var title_f8_47_8944="Calcified granuloma CT";
var content_f8_47_8944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcified pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Benign pattern of calcification in a solitary pulmonary nodule. There is diffuse calcification in this subpleural nodular granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8944=[""].join("\n");
var outline_f8_47_8944=null;
var title_f8_47_8945="Irving tubal ligation B";
var content_f8_47_8945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irving tubal ligation B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8945=[""].join("\n");
var outline_f8_47_8945=null;
var title_f8_47_8946="Plasma cell granuloma high";
var content_f8_47_8946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification photomicrograph showing a combination of spindle cells and plasma cells in inflammatory myofibroblastic tumor (plasma cell granuloma). The spindle cells likely represent the most important distinguishing feature and show immunophenotypic and ultrastructural characteristics of myofibroblasts. Although plasma cells account for most of the inflammatory cells in this example, it is not uncommon to see associated histiocytes, including lipid-laden foam cells and multinucleated giant cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8946=[""].join("\n");
var outline_f8_47_8946=null;
var title_f8_47_8947="Patient information: Closed head injury (The Basics)";
var content_f8_47_8947=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17111\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/49/31507\">",
"         Skull bones",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37905\">",
"         Patient information: Coma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/12/22722\">",
"         Patient information: Concussion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/45/40658\">",
"         Patient information: Head injury in children and adolescents (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/24/34178\">",
"         Patient information: Skull and facial fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/59/41905\">",
"         Patient information: Vertigo (a type of dizziness) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/31/41460\">",
"         Patient information: Dizziness and vertigo (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/44/14020\">",
"         Patient information: Head injury in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/51/16179\">",
"         Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/15/36086\">",
"         Patient information: Headache in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/26/419\">",
"         Patient information: Seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Closed head injury (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/closed-head-injury-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28339969\">",
"      <span class=\"h1\">",
"       What is a closed head injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A closed head injury is when an object hits and hurts the head, but doesn&rsquo;t go through the skull. Even though the object doesn&rsquo;t go through the skull, parts of the head can still get damaged. A closed head injury can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A broken bone of the skull or face (",
"        <a class=\"graphic graphic_figure graphicRef62443 \" href=\"UTD.htm?30/49/31507\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Brain injury or swelling &ndash; Another word for a mild brain injury is a &ldquo;concussion.&rdquo;",
"       </li>",
"       <li>",
"        Bleeding in or around the brain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The most common causes of a closed head injury are falls, sports injuries, and car and bike accidents.",
"     </p>",
"     <p>",
"      Some closed head injuries are mild, but others are severe and life-threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28339984\">",
"      <span class=\"h1\">",
"       What are the symptoms of a closed head injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on the type of injury a person has and how severe it is. People with a mild closed head injury, such as a bump on the head, might not have any symptoms.",
"     </p>",
"     <p>",
"      When a closed head injury does cause symptoms, it can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A headache",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Swelling, bleeding, or bruising on the scalp",
"       </li>",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Confusion or memory problems",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Mood or behavior changes",
"       </li>",
"       <li>",
"        Trouble walking or talking",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain. They can make you pass out, or move or behave strangely.",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A closed head injury that involves a broken skull or face bone can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bruising around the eyes or behind the ear",
"       </li>",
"       <li>",
"        Blood or clear fluid draining from the nose or ear",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms can start right after a closed head injury, or a few hours or days later. Some people have symptoms that last a short time only. Other people have symptoms that cause long-lasting problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28339999\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your injury and symptoms. Your doctor or nurse will ask about your symptoms and do an exam. He or she will also ask questions to check your thinking.",
"     </p>",
"     <p>",
"      If your doctor or nurse thinks you might have a serious injury, he or she might order an imaging test of your brain, such as a CT or MRI scan. These tests create pictures of your skull and brain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28340014\">",
"      <span class=\"h1\">",
"       How is a closed head injury treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your injury and how serious it is.",
"     </p>",
"     <p>",
"      Usually, mild closed head injuries do not need treatment. But your doctor might recommend that someone watch you for 24 hours after your injury. This person should watch for new symptoms or the symptoms listed above. If you fall asleep, he or she should wake you up every few hours to make sure that you can be woken up.",
"     </p>",
"     <p>",
"      Severe closed head injuries need to be treated in the hospital. Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Different medicines &ndash; Some medicines help prevent brain swelling. Others help prevent seizures.",
"       </li>",
"       <li>",
"        Surgery &ndash; If you have bleeding in or around your brain, or if your brain swells, you might need surgery. Doctors can do different types of surgery to treat these problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28340029\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After your closed head injury, call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your headache gets worse.",
"       </li>",
"       <li>",
"        You vomit.",
"       </li>",
"       <li>",
"        Your thinking or behavior changes.",
"       </li>",
"       <li>",
"        You can&rsquo;t walk normally.",
"       </li>",
"       <li>",
"        You have a seizure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Plus, the person watching you should call the doctor or nurse if he or she can&rsquo;t wake you up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28340044\">",
"      <span class=\"h1\">",
"       When can I play sports or do my usual activities again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor when you can play sports or do your usual activities again. It will depend on your injury and symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28340059\">",
"      <span class=\"h1\">",
"       How can I prevent another closed head injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent another closed head injury, you should wear a helmet when you ride a bike or motorcycle, or play sports where you could get hurt. You should also wear a seat belt every time you drive or ride in a car.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28340074\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=see_link\">",
"       Patient information: Head injury in children and adolescents (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/12/22722?source=see_link\">",
"       Patient information: Concussion (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=see_link\">",
"       Patient information: Skull and facial fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41905?source=see_link\">",
"       Patient information: Vertigo (a type of dizziness) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37905?source=see_link\">",
"       Patient information: Coma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=see_link\">",
"       Patient information: Head injury in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=see_link\">",
"       Patient information: Dizziness and vertigo (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"       Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=see_link\">",
"       Patient information: Headache in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=see_link\">",
"       Patient information: Seizures in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/47/8947?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17111 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8947=[""].join("\n");
var outline_f8_47_8947=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28339969\">",
"      What is a closed head injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28339984\">",
"      What are the symptoms of a closed head injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28339999\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28340014\">",
"      How is a closed head injury treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28340029\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28340044\">",
"      When can I play sports or do my usual activities again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28340059\">",
"      How can I prevent another closed head injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28340074\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17111\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/49/31507\">",
"      Skull bones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37905?source=related_link\">",
"      Patient information: Coma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=related_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=related_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=related_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8948="Idursulfase: Patient drug information";
var content_f8_47_8948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Idursulfase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36307?source=see_link\">",
"     see \"Idursulfase: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3151893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elaprase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5376743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elaprase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10014698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700553",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have lung disease. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Hunter syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to idursulfase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Diphenhydramine may be given before this drug to lower itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11767 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-B0D0D57A02-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8948=[""].join("\n");
var outline_f8_47_8948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151893\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376743\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014698\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014700\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014699\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014704\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014705\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014707\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014702\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014703\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014708\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014709\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36307?source=related_link\">",
"      Idursulfase: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8949="Sulfadoxine and pyrimethamine: Pediatric drug information";
var content_f8_47_8949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfadoxine and pyrimethamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"    see \"Sulfadoxine and pyrimethamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/43/2742?source=see_link\">",
"    see \"Sulfadoxine and pyrimethamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fansidar&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"      see \"Sulfadoxine and pyrimethamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge; 2 months and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of acute attack of malaria: A single dose of the following number of Fansidar&reg; tablets is used in sequence with quinine on last day of quinine therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-11 months:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1 tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-14 years: 2 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;14 years: 3 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3 tablets on last day of quinine therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Malaria prophylaxis (for areas where chloroquine-resistant",
"     <i>",
"      P. falciparum",
"     </i>",
"     exists):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Short-term travel (&le;3 weeks): Travelers should carry pyrimethamine-sulfadoxine for use as presumptive self-treatment if a febrile illness develops while taking chloroquine for prophylaxis. Take single dose in the event of febrile illness when medical attention is not immediately available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-11 months:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 1 tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-14 years: 2 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;14 years and Adults: 3 tablets",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fansidar&reg;: Sulfadoxine 500 mg and pyrimethamine 25 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     malaria in patients in whom chloroquine resistance is suspected; malaria prophylaxis for travelers to areas where chloroquine-resistant malaria is endemic",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F223861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Myocarditis (allergic), pericarditis (allergic), periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, hallucinations, headache, polyneuritis, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, photosensitivity, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid function dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, atrophic glossitis, gastritis, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: increased BUN, increased serum creatinine, interstitial nephritis, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Alveolitis (resembling eosinophilic or allergic) respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, drug fever, hypersensitivity, lupus-like syndrome, periarteritis nodosum",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any sulfa drug, pyrimethamine, or any component; megaloblastic anemia due to folate deficiency; children &lt;2 months of age (due to competition with bilirubin for protein binding sites); pregnant women at term; breast-feeding; repeated prophylactic use in patients with renal or hepatic failure or with blood dyscrasias",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment, patients with possible folate deficiency, patients with bronchial asthma, and patients with seizure disorders. Avoid excess sun exposure.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities associated with sulfonamides, although rare, have occurred due to severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; discontinue use at first sign of rash or any sign of adverse reaction; hemolysis may occur in patients with G-6-PD deficiency",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F223853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sulfonamide Derivatives may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Sulfonamide Derivatives may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Sulfonamide Derivatives may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May diminish the therapeutic effect of Pyrimethamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Sulfonamide Derivatives may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procaine: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Sulfonamide Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonamide Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Pyrimethamine and sulfadoxine both cross the placenta. Prophylactic use near term is contraindicated by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, CBC including platelet counts, renal function tests and urinalysis should be performed periodically",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfadoxine interferes with bacterial folic acid synthesis and growth via competitive inhibition of para-aminiobenzoic acid; pyrimethamine inhibits microbial dihydrofolate reductase, resulting in inhibition of tetrahydrofolic acid synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Excreted in breast milk; pyrimethamine is distributed to kidneys, lungs, liver, and spleen; sulfadoxine is widely distributed in the body",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyrimethamine: 80% to 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfadoxine: 90% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyrimethamine: 111 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfadoxine: 169 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as parent compounds and several unidentified metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/43/2742?source=see_link\">",
"      see \"Sulfadoxine and pyrimethamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of fluids; notify physician if rash, sore throat, pallor, glossitis, fever, arthralgia, cough, shortness of breath, or jaundice occurs; limit alcohol. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leucovorin calcium should be administered to reverse signs and symptoms of folic acid deficiency",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lynk A and Gold R, &ldquo;Review of 40 Children With Imported Malaria,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):745-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/47/8949/abstract-text/2594448 /pubmed\" id=\"2594448 \" target=\"_blank\">",
"        2594448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Randall G and Seidel JS, &ldquo;Malaria,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1985, 32(4):893-916.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/47/8949/abstract-text/3895138/pubmed\" id=\"3895138\" target=\"_blank\">",
"        3895138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12815 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8949=[""].join("\n");
var outline_f8_47_8949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709421\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050032\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050025\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223830\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223815\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050035\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050028\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050034\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223861\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050038\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050024\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050023\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223853\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223826\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287361\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050031\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050022\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050037\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050030\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050039\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=related_link\">",
"      Sulfadoxine and pyrimethamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/43/2742?source=related_link\">",
"      Sulfadoxine and pyrimethamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8950="Low back pain in adults";
var content_f8_47_8950=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Low back pain in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/47/8950/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8950/contributors\" id=\"au1746\">",
"       Roger Chou, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/47/8950/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8950/contributors\" id=\"se1340\">",
"       Steven J Atlas, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/47/8950/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8950/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?8/47/8950?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LOW BACK PAIN OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Low back pain is one of the most common disorders in the United States. About 80 percent of people have at least one episode of low back pain during their lifetime.",
"    </p>",
"    <p>",
"     Factors that increase the risk of developing low back pain include smoking, obesity, older age, female gender, physically strenuous work, sedentary work, a stressful job, job dissatisfaction and psychological factors such as anxiety or depression.",
"    </p>",
"    <p>",
"     This topic review will focus on recovery from low back pain within the first one to two months. Back pain in children and adolescents is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/51/22320?source=see_link\">",
"      \"Patient information: Back pain in children and adolescents (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information is also available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"      \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      STRUCTURE OF THE BACK",
"     </span>",
"    </p>",
"    <p>",
"     The back is formed by bones, muscles, nerves, and other tissues that work together to help us stand and bend. The bones of the back are called vertebrae, which together form the spinal column. The spinal column protects the spinal cord, part of the central nervous system that controls our ability to feel and move.",
"    </p>",
"    <p>",
"     The spinal cord passes through an opening on the back of the vertebrae. The vertebrae are stacked one on top of another. Small nerves (called nerve roots) exit from the spinal cord and pass through spaces on the sides of the vertebrae. The spinal column extends below the base of the spinal cord. The nerve roots to the lower back and legs are together called the cauda equina, or horse's tail.",
"    </p>",
"    <p>",
"     Between each pair of vertebrae in the spinal column is a disc composed of a tough outer tissue and a gel-like inner pulp. These discs protect the bones, acting like cushions or shock absorbers. The vertebrae are held together by ligaments and tendons, allowing the vertebrae to move together as the spinal column bends forwards, backwards, and side to side.",
"    </p>",
"    <p>",
"     There are four main regions of the back; the cervical (C), thoracic (T), lumbar (L), and sacral (S) regions (",
"     <a class=\"graphic graphic_figure graphicRef82142 \" href=\"UTD.htm?28/9/28819\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The 7 cervical vertebrae are located in the neck",
"      </li>",
"      <li>",
"       The 12 thoracic vertebrae are located in the upper back",
"      </li>",
"      <li>",
"       The 5 lumbar vertebrae are located in the lower back",
"      </li>",
"      <li>",
"       The sacrum and coccyx are fused bones, found at the base of the spinal column",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The vertebrae are numbered from top to bottom. As an example, the top lumbar vertebra is called the L1 vertebra. Low back pain occurs in the area of the lumbar and sacral vertebrae, most commonly at L4, L5, and S1.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      LOW BACK PAIN CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Low back pain can have many causes. However, most people (&gt;85 percent) have \"nonspecific low back pain\", which is not caused by a specific disease or abnormality in the spine. Many people attribute their back pain to a degenerating disc or arthritis, although problems in muscles or ligaments or other causes may be equally responsible (",
"     <a class=\"graphic graphic_figure graphicRef56246 \" href=\"UTD.htm?4/51/4917\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Rarely, back pain is caused by a potentially serious spinal condition, such as infection, fracture, or tumor, or a disorder called cauda equina syndrome, which causes weakness and bowel or bladder dysfunction as well as back pain. Back pain that is associated with leg pain can be due to a herniated disc or spinal stenosis. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Lumbar spinal stenosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Degenerative disc disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Wear and tear can lead to degenerative disc disease, or the breakdown of the spinal discs, with small cracks and tears",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     loss of fluid in the discs. &nbsp;This can lead to other changes including the formation of bone spurs. Calling this condition a \"disease\" is somewhat misleading because these changes occur with normal aging and frequently cause no symptoms. In fact, many people have degenerative disc disease seen on x-rays or other imaging studies but have no pain or other symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Facet joint arthropathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Facet joint arthropathy refers to arthritis in the joints connecting the vertebrae to one another (facet joints). This can lead to bone spurs around the joint and may cause low back pain. However, like degenerative disc disease, facet joint arthropathy is very common with aging and many people have no symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Spondylolisthesis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Spondylolisthesis is a condition in which one of the vertebrae of the lower spine slips forward in relation to another. Spondylolisthesis is usually caused by stress on the joints of the lower back and may be associated with facet joint arthropathy. Although this condition can cause low back pain and sciatica, sometimes it causes no symptoms at all and is diagnosed with an x-ray done for another reason.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Herniated disc",
"     </span>",
"     &nbsp;&mdash;&nbsp;Too much wear and tear on spinal discs can lead to herniation of a disc, in which the outer covering is weakened or torn, and the soft inner tissue extrudes (a \"slipped disc\"). Herniated discs can cause leg pain or weakness if the disc pinches a nerve root (",
"     <a class=\"graphic graphic_figure graphicRef64922 \" href=\"UTD.htm?19/5/19542\">",
"      figure 3",
"     </a>",
"     ). However, herniated discs are frequently seen on x-rays, even in people with no low back pain. Herniated discs usually heal over time because the body breaks down the excess disc material and water within the disc is absorbed, relieving pressure or irritation on the nerve.",
"    </p>",
"    <p>",
"     A bulging disc protrudes less than a herniated disc. It is more common than a herniated disc and is seen in half of people who have no back pain. A bulging disc usually causes no symptoms, although occasionally it can cause sciatica. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Sciatica'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Lumbar spinal stenosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Spinal stenosis is a condition in which the vertebral canal (the open space inside the vertebrae) is narrowed. This is often caused by inflammation due to one or more damaged discs, and is particularly common in older patients. Spinal stenosis can cause neurogenic claudication. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Neurogenic claudication'",
"     </a>",
"     below.) However, like herniated discs, spinal stenosis can be seen in people with no symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Less common causes of low back pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rarely, low back pain is caused by a serious spinal condition, such as an infection, tumor, or a disorder called cauda equina syndrome, which causes weakness and bowel or bladder dysfunction as well as low back pain. Other potential causes include spinal compression fractures, in which one or more vertebrae become fractured as a result of weakening and thinning of the vertebrae due to osteoporosis.",
"    </p>",
"    <p>",
"     In younger people, low back pain with morning stiffness can be associated with an inflammatory condition called ankylosing spondylitis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"      \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Back pain and work",
"     </span>",
"     &nbsp;&mdash;&nbsp;Factors that may contribute to low back pain at work include poor posture while sitting or standing, sitting or standing for long periods of time, driving long distances, improper lifting techniques, frequent lifting, or lifting excessively heavy loads. Low back pain is as common among clerical workers who sit for prolonged periods as in people whose jobs require heavy lifting",
"    </p>",
"    <p>",
"     Psychological factors can contribute to low back pain. These include stress, job dissatisfaction, boredom, tension, as well as how the body responds to everyday physical demands. Workplace stress can be managed with counseling; a number of techniques are available. Resolving these psychological factors improves a person's chances of recovering from low back pain.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      LOW BACK PAIN SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Radiculopathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A common feature of low back pain is radiculopathy, which occurs when a nerve root is irritated by a protruding disc or arthritis of the spine. Radiculopathies usually cause radiating pain, numbness, tingling, or muscle weakness in the specific areas related to the affected nerve root, usually the lower leg. Most people with these conditions improve with limited or no treatment, described below. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Low back pain treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sciatica",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sciatica refers to the most common symptom of radiculopathy. It is a pain that occurs when one of the five spinal nerve roots, which are branches of the sciatic nerve, is irritated, causing a sharp or burning pain that extends down the back or side of the thigh, usually to the foot or ankle. You may also feel numbness or tingling. If a disc is herniated, sciatic pain often increases with coughing, sneezing, or bearing down.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Neurogenic claudication",
"     </span>",
"     &nbsp;&mdash;&nbsp;Neurogenic claudication is a type of pain that runs down the back to the buttocks, thighs, and lower legs, often involving both sides of the body. This may cause limping and weakness in the legs. Pain usually gets worse when extending the lower spine (eg, when standing or walking), and gets better when flexing the spine by sitting, stooping, or leaning forward.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with low back pain should be managed by a primary care or family medicine provider. If low back pain is caused by a serious condition, a neurosurgeon or orthopedist who specializes in back surgery is usually recommended. People who have any of the following should contact their healthcare provider for advice:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you are 70 years or older with new back pain",
"      </li>",
"      <li>",
"       Pain that does not go away, even at night or when lying down.",
"      </li>",
"      <li>",
"       Weakness in one or both legs or problems with bladder, bowel, or sexual function can be signs of cauda equina syndrome, arising from compression of the nerve bundle at the base of the spine. These symptoms should be evaluated as soon as possible.",
"      </li>",
"      <li>",
"       If you have back pain accompanied by unexplained fever or weight loss",
"      </li>",
"      <li>",
"       If you have a history of cancer, a weakened immune system, osteoporosis, or have used corticosteroids (eg, prednisone) for a prolonged period of time",
"      </li>",
"      <li>",
"       If the back pain is a result of falling or an accident, especially if you are older than 50 years.",
"      </li>",
"      <li>",
"       If pain spreads into the lower leg, particularly if accompanied by weakness of the leg.",
"      </li>",
"      <li>",
"       If back pain does not improve within four weeks.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      LOW BACK PAIN TESTS",
"     </span>",
"    </p>",
"    <p>",
"     The vast majority of people with low back pain improve within 4 to 6 weeks without treatment or with simple measures that can be performed at home. It is not usually necessary to consult a healthcare provider if the pain improves [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/1\">",
"      1",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=see_link\">",
"      \"Diagnostic testing for low back pain\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imaging tests, including plain x-rays, CT (computed tomography) scanning, or an MRI (magnetic resonance imaging), may be recommended for people with certain conditions [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      X-rays",
"     </span>",
"     &nbsp;&mdash;&nbsp;X-rays may be recommended for selected people who have risk factors or signs of infection, cancer, or vertebral compression fracture related to osteoporosis. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'When to seek help'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     However, x-rays do not usually show enough detail to diagnose a herniated disc or spinal stenosis. Other common conditions, such as degenerative disc disease, facet joint arthropathy, and disc space narrowing, are seen so frequently in people without low back pain that it is usually not helpful to get x-rays to look for these, especially since their presence does not change treatment in the first 4 to 6 weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      CT and MRI",
"     </span>",
"     &nbsp;&mdash;&nbsp;CT scanning and MRI provide detailed images of the soft tissues and bony structures of the back. A CT or MRI is usually necessary to diagnose a herniated disc or spinal stenosis. One of these tests may be recommended if surgery is being considered or if low back pain persists for more than 4 to 6 weeks and the cause of pain cannot be determined with other methods.",
"    </p>",
"    <p>",
"     However, most people with low back pain do not require a CT or MRI. Disc and spine abnormalities are common among people without low back pain. In fact, a herniated disc is seen on MRI or CT in 25 percent of people without low back pain.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      LOW BACK PAIN TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Unless low back pain is caused by a serious medical condition, a rapid recovery is expected, even if there is a bulging or herniated disc. The body breaks down bulging discs, taking pressure off the nerve. Care of an attack of low back pain includes several simple elements. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link\">",
"      \"Treatment of acute low back pain\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Remaining active",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people are afraid that they will hurt their back further or delay recovery by remaining active. However, remaining active is one of the best things you can do for your back. In fact, prolonged bed rest is not recommended. Studies have shown that people with low back pain recover faster when they remain active. Movement helps to relieve muscle spasms and prevents loss of muscle strength.",
"    </p>",
"    <p>",
"     Although high-impact activities should be avoided, it is fine to continue doing regular day-to-day activities and light exercises, such as walking. If certain activities cause the back to hurt too much, it is fine to stop that activity and try another.",
"    </p>",
"    <p>",
"     If back pain is severe, bedrest may be necessary for a short period of time, generally no more than one day [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/3\">",
"      3",
"     </a>",
"     ]. When in bed, the most comfortable position may be to lie on the back with a pillow behind the knees and the head and shoulders elevated, or to lie on the side with the upper knee bent and a pillow between the knees.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Heat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Using a heating pad can help with low back pain during the first few weeks. It is not clear if cold packs help as well [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Work",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most experts recommend that people with low back pain continue to work so long as it is possible to avoid prolonged standing or sitting, heavy lifting, and twisting. Some people need to stay home from work if their occupation does not allow them to sit or stand comfortably. While standing at work, stepping on a block of wood with one foot (and periodically alternating the foot on the block) may be helpful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Pain medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Take a pain medication such as aspirin, acetaminophen (Tylenol&reg;), or ibuprofen (eg, Advil&reg;) or naproxen (Aleve&reg;). Stronger pain medications, such as opioids, are reserved for people whose pain is not relieved with acetaminophen or NSAIDs.",
"    </p>",
"    <p>",
"     If medication is needed, it is usually more effective to take a dose on a regular basis for three to five days, rather than using the medication only when the pain becomes unbearable. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Muscle relaxants (eg, cyclobenzaprine, Flexeril&reg;) are available by prescription, but can cause drowsiness and are probably no better than ibuprofen in relieving pain [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/5\">",
"      5",
"     </a>",
"     ]. Muscle relaxants may be helpful before bedtime when used for a short time. People who need to be alert, such as while driving or operating machinery, should not use muscle relaxants.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Back exercises or stretching routines should not be used immediately after a new episode of low back pain because this could worsen or prolong pain. However, as symptoms begin to resolve, a program of exercises can help to increase back flexibility and strengthen the muscles that support the back [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Recommended activities include those that involve strengthening and stretching, such as walking, swimming, use of a stationary bicycle, and low-impact aerobics. Avoid activities that involve twisting, bending, are high impact, or that make the back hurt more. Some specific exercises may help strengthen the muscles of the lower back. People with frequent episodes of low back pain should continue these exercises indefinitely to prevent new episodes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Physical therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If back pain has been present for more than 4 to 6 weeks, a healthcare provider may recommend working with a physical therapist to develop a formal exercise program. Exercise programs may involve stretching, flexion and extension exercises, strengthening, aerobic activity, general overall fitness, or some combination of these components. The physical therapist may directly supervise exercise sessions, or can teach the person to perform the exercise program at home.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Manipulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Manipulation is a technique used by physical therapists, chiropractors, osteopaths, massage therapists, and others to treat acute and chronic back pain. It involves moving a joint (spinal column) beyond the normal range of voluntary movement.",
"    </p>",
"    <p>",
"     In clinical trials of people who had back pain for more than 4 weeks, manipulation was found to be safe and as effective as \"conventional\" treatments (eg, pain medication, rest, exercise) [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/7\">",
"      7",
"     </a>",
"     ]. The optimal number of manipulations is not known; most clinical trials used two treatments per week for two to three weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Acupuncture",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acupuncture involves inserting very fine needles into specific points, as determined by traditional Chinese maps of the body's flow of energy. Acupuncture may be a reasonable option for interested patients with access to an acupuncturist. In general, acupuncture is a safe treatment that may be helpful for chronic back pain [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/8\">",
"      8",
"     </a>",
"     ]. It is not clear if acupuncture is helpful for people with recent-onset (acute) low back pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Massage and yoga",
"     </span>",
"     &nbsp;&mdash;&nbsp;A few studies have evaluated massage and yoga for back pain treatment. The benefit of massage or yoga was found to be greatest in people with chronic back pain who expected to improve with one of these treatments [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/9\">",
"      9",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H18#H18\">",
"      \"Fish oil and marine omega-3 fatty acids\", section on 'Total mortality'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Other treatments",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Injections &mdash; Some clinicians recommend injections of a local anesthetic into the soft tissues of the back to relieve chronic pain, although it is not clear if these injections are effective. The areas targeted by these injections are called trigger points. Trigger point injections may be of benefit in people with chronic back pain.",
"       <br/>",
"       <br/>",
"       Injections of a steroid medication are sometimes recommended for people with chronic low back pain with sciatica or radiculopathy. The injection is given into the epidural space, located below the spinal cord. Epidural steroid injections do appear to improve pain slightly at two and six weeks after the injection, but not at 3, 6, or 12 months after the injection. There is no evidence that epidural steroid injections are helpful for people with back pain without sciatica.",
"      </li>",
"      <li>",
"       Corsets and braces are not helpful in treating or preventing low back pain.",
"      </li>",
"      <li>",
"       Traction involves the use of weights to realign or pull the spinal column into alignment. Clinical studies have shown no benefit from traction in the treatment of back pain in the first few weeks.",
"      </li>",
"      <li>",
"       Mattress choice &mdash; The benefit of a firm mattress in preventing or treating low back pain has not been proven. In one study, medium firm mattresses were more likely to improve chronic back pain compared to firm mattresses [",
"       <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/10\">",
"        10",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       Other interventions include ultrasound, interferential therapy, short-wave diathermy transcutaneous electrical nerve stimulation, low-level laser therapy, all of which involve applying energy to the skin's surface. &nbsp;None of these interventions have been proven to be effective, particularly during the first four to six weeks of an episode of back pain.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31\">",
"     <span class=\"h2\">",
"      Chronic low back pain treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Long-term (chronic) back pain treatments are discussed in detail separately and are available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"      \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"      \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H32\">",
"     <span class=\"h1\">",
"      LOW BACK PAIN SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Only a small minority of people with low back pain will require surgery. Surgery",
"     <strong>",
"      is",
"     </strong>",
"     often necessary if there is evidence of cauda equina syndrome (problems with the nerves at the base of the spinal cord), another serious back condition like a tumor or infection, or severe weakness due to spinal stenosis or compression of a nerve root. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"      \"Subacute and chronic low back pain: Surgical treatment\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Surgery may also be considered for people with persistent radiculopathy due to herniated disc or spinal stenosis that has not responded to other (non-surgical) therapies. There is controversy about whether surgery is beneficial for people with degenerative disc disease alone.",
"    </p>",
"    <p>",
"     Referral to an orthopedic surgeon or neurosurgeon is recommended under the following circumstances:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Increasing neurologic problems (measurable weakness)",
"      </li>",
"      <li>",
"       Loss of sensation (eg, numbness) or bladder and bowel symptoms",
"      </li>",
"      <li>",
"       Failure to improve after four to six weeks of non-surgical management, with persistent and severe sciatica and evidence of nerve root involvement",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H33\">",
"     <span class=\"h1\">",
"      PREVENTING LOW BACK PAIN",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of ways to prevent low back pain from returning. Perhaps the most important are exercise and staying active. Regular exercise that improves cardiovascular fitness can be combined with specific exercises to strengthen the muscles of the hips and torso. The abdominal muscles are particularly important in supporting the lower back and preventing back pain. It is also important to avoid activities that involve repetitive bending or twisting and high-impact activities that increase stress in the spine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H34\">",
"     <span class=\"h2\">",
"      Bend and lift correctly",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with low back pain should learn the right way to bend and lift. As an example, lifting should always be done with the knees bent and the abdominal muscles tightened to avoid straining the weaker muscles in the lower back (",
"     <a class=\"graphic graphic_picture graphicRef72751 \" href=\"UTD.htm?14/18/14625\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H35\">",
"     <span class=\"h2\">",
"      Take a break",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who sit or stand for long periods should change positions often and use a chair with appropriate support for the back. An office chair should be readjusted several times throughout the day to avoid sitting in the same position. Taking brief but frequent breaks to walk around will also prevent pain due to prolonged sitting or standing. People who stand in place for long periods can try placing a block of wood on the floor, stepping up and down every few minutes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H36\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H361\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20923699\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=see_link\">",
"      Patient information: Spinal stenosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=see_link\">",
"      Patient information: Herniated disc (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/20/18754?source=see_link\">",
"      Patient information: Scoliosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11522?source=see_link\">",
"      Patient information: Cauda equina syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/16/33026?source=see_link\">",
"      Patient information: Do I need imaging for low back pain? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/8/32898?source=see_link\">",
"      Patient information: Radiculopathy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20923717\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/51/22320?source=see_link\">",
"      Patient information: Back pain in children and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23746?source=see_link\">",
"      Patient information: Chronic pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H38\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"      Acupuncture",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=see_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=see_link\">",
"      Diagnostic testing for low back pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6841?source=see_link\">",
"      Exercise-based therapy for low back pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=see_link\">",
"      Lumbar spinal stenosis: Treatment and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=see_link\">",
"      Musculoskeletal changes and pain during pregnancy and postpartum",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42535?source=see_link\">",
"      Occupational low back pain: Evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link\">",
"      Occupational low back pain: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=see_link\">",
"      Spinal manipulation in the treatment of musculoskeletal pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link\">",
"      Treatment of acute low back pain",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/backpain/detail_backpain.htm\">",
"      www.ninds.nih.gov/disorders/backpain/detail_backpain.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"      file://orthoinfo.aaos.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?8/47/8950/abstract/1-7,9,10\">",
"      1-7,9,10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?8/47/8950?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/1\">",
"      Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/2\">",
"      Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med 2002; 137:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/3\">",
"      Hagen KB, Hilde G, Jamtvedt G, Winnem M. Bed rest for acute low-back pain and sciatica. Cochrane Database Syst Rev 2004; :CD001254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/4\">",
"      French SD, Cameron M, Walker BF, et al. Superficial heat or cold for low back pain. Cochrane Database Syst Rev 2006; :CD004750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/5\">",
"      Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/6\">",
"      Hayden JA, van Tulder MW, Malmivaara AV, Koes BW. Meta-analysis: exercise therapy for nonspecific low back pain. Ann Intern Med 2005; 142:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/7\">",
"      Assendelft WJ, Morton SC, Yu EI, et al. Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other therapies. Ann Intern Med 2003; 138:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/8\">",
"      Furlan AD, van Tulder MW, Cherkin DC, et al. Acupuncture and dry-needling for low back pain. Cochrane Database Syst Rev 2005; :CD001351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/9\">",
"      Chou R, Huffman LH, American Pain Society, American College of Physicians. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8950/abstract/10\">",
"      Kovacs FM, Abraira V, Pe&ntilde;a A, et al. Effect of firmness of mattress on chronic non-specific low-back pain: randomised, double-blind, controlled, multicentre trial. Lancet 2003; 362:1599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f8_47_8950=[""].join("\n");
var outline_f8_47_8950=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LOW BACK PAIN OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           STRUCTURE OF THE BACK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           LOW BACK PAIN CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           LOW BACK PAIN SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           LOW BACK PAIN TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           LOW BACK PAIN TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H32\">",
"           LOW BACK PAIN SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H33\">",
"           PREVENTING LOW BACK PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H36\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/9/28819\" title=\"figure 1\">",
"           Regions of back PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\" title=\"figure 2\">",
"           Back anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/5/19542\" title=\"figure 3\">",
"           Herniated disc PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14625\" title=\"picture 1\">",
"           Lifting techniques PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8951="Experimental approaches to treatment for small cell lung cancer";
var content_f8_47_8951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Experimental approaches to treatment for small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8951/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8951/contributors\">",
"     Karen Kelly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8951/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8951/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/47/8951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung cancer (SCLC) is distinguished from non-small cell lung cancer (NSCLC) by its rapid doubling time, high growth fraction, and the early development of metastases. Although SCLC is highly responsive to both chemotherapy and radiotherapy (RT), it commonly relapses within months despite treatment.",
"   </p>",
"   <p>",
"    Since SCLC usually presents with disseminated disease, treatment strategies have focused on systemic chemotherapy. Although this has resulted in significant improvements in survival for patients with both limited and extensive stage disease, the long-term prognosis remains poor.",
"   </p>",
"   <p>",
"    Attempts to further improve survival with chemotherapy have included the evaluation of higher dose therapy including bone marrow transplantation, dose dense regimens, alternating non-cross resistant treatments and novel cytotoxic agents. However, these approaches have not resulted in major advances in the treatment of SCLC in more than twenty years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H23#H23\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Increased dose intensity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigational approaches for the treatment of SCLC will be reviewed here. Standard approaches to chemotherapy in patients with SCLC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in understanding the pathogenesis of SCLC had identified a number of new targets at the molecular level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     IGF-1R inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin-like growth factor 1 receptor (IGF-1R) pathway is a potent autocrine growth factor pathway that appears to be involved in the pathogenesis of SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/1\">",
"     1",
"    </a>",
"    ]. Binding of IGF-1, or IGF-2 to a lesser extent, to IGF-1R results in a conformational change in the receptor that leads to its activation. The activated receptor then recruits insulin receptor substrate (IRS) that serves as a docking protein to link the receptor to the PI3 kinase and the MAP kinase pathways, resulting in cellular proliferation and inhibition of programmed cell death.",
"   </p>",
"   <p>",
"    Preclinical data has provided a basis for clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cixitumumab is a monoclonal antibody that binds to the IGF-1R, thus blocking binding with IGF-1 and preventing activation of these pathways. A phase II trial combining cixutumumab with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      has completed accrual (NCT00887159); results are pending.",
"     </li>",
"     <li>",
"      Linsitinib is an orally available, selective small molecule inhibitor of IGF-1R. A phase II trial comparing linsitinib with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      is recruiting patients (NCT01387386).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885061972\">",
"    <span class=\"h2\">",
"     PI3K/Akt/mTOR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;This pathway is a critical regulator of cell survival and is essential for oncogenic transformation. It is activated through a number of tyrosine kinase growth factor receptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    , an inhibitor of mammalian target of rapamycin (mTOR), has been evaluated as a maintenance agent after induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/2\">",
"     2",
"    </a>",
"    ]. In this setting, there was no indication of improvement in survival compared with historical controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H982488532\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in PI3K and PTEN have been identified in SCLC. Clinical trials with PI3K inhibitors and AKT inhibitors are planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062067\">",
"    <span class=\"h2\">",
"     Hedgehog inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hedgehog pathway is activated in SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/3\">",
"     3",
"    </a>",
"    ]. A phase II study of the hedgehog inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    versus cisplatin and etoposide has completed accrual (NCT00887159); results are pending. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link&amp;anchor=H7#H7\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\", section on 'Vismodegib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568140996\">",
"    <span class=\"h2\">",
"     Alisertib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alisertib is an oral, selective Aurora A kinase inhibitor. In a phase II study of alisertib (50 mg twice a day for 14 days every 21 days), four partial responses were observed among the 26 patients (15 percent) with relapsed SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568140817\">",
"    <span class=\"h2\">",
"     Tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different tyrosine kinase inhibitors targeting c-kit, EGFR, and Src have been studied in patients with SCLC. However, none of these have had significant clinical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062095\">",
"    <span class=\"h2\">",
"     Apoptosis modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apoptosis modulator bcl-2 is frequently abnormal in SCLC. However, targeted therapy directed at this and other proapoptotic proteins have not demonstrated significant clinical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H982489764\">",
"    <span class=\"h2\">",
"     Other classes of molecular therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various other classes of molecular therapies are also being evaluated in patients with SCLC including PARP inhibitors and HDAC inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANGIOGENESIS INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiogenesis is necessary for tumor growth and metastasis. Pathologic studies in resected SCLC specimens revealed that high microvessel count and vascular endothelial growth factor (VEGF) expression were associated with decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Furthermore, VEGF expression was shown to be an independent poor prognostic factor, as was a high pretreatment level of VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is an angiogenesis inhibitor with significant biologic activity that has been linked to abnormal angiogenesis. Thalidomide also exhibits potent immunomodulatory effects in addition to its antiangiogenic properties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H117146124#H117146124\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Imunomodulatory drugs (IMiDs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two phase III trials evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in extensive stage-SCLC (ES-SCLC):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a European trial that was stopped prematurely due to poor accrual, 119 patients who had responded to chemotherapy were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or placebo after their initial chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/14\">",
"       14",
"      </a>",
"      ]. The increase in survival with thalidomide was not statistically significant (median 11.7 versus 8.7 months with placebo). The thalidomide regimen was associated with an unacceptable level of neurotoxicity.",
"     </li>",
"     <li>",
"      In a second trial, 724 patients were randomly assigned to chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ) with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/15\">",
"       15",
"      </a>",
"      ]. There was no significant improvement in survival with thalidomide (10.5 versus 10.2 months), and there was higher incidence of thrombotic events with thalidomide (18 versus 11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a monoclonal antibody that binds to VEGF, thus inhibiting neoangiogenesis and normalizing tumor vasculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    has been combined with platinum-based chemotherapy in three multicenter phase II studies in previously untreated patients with ES-SCLC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 102 patients were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or placebo in combination with a platinum compound (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/16\">",
"       16",
"      </a>",
"      ]. Progression-free survival was significantly increased with bevacizumab compared with placebo (median 5.5 versus 4.4 months, hazard ratio [HR] 0.53). However, there was no improvement in overall survival (median 9.4 versus 10.9 months, HR 1.16).",
"     </li>",
"     <li>",
"      In an ECOG trial, 63 patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/17\">",
"       17",
"      </a>",
"      ]. The median progression-free survival and overall survival were 4.7 and 10.9 months, respectively, which was longer than historical controls treated without bevacizumab.",
"     </li>",
"     <li>",
"      In a CALGB study, 72 patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/18\">",
"       18",
"      </a>",
"      ]. Median progression-free survival and overall survival were 7.0 and 11.6 months, respectively. Although these results were better than those seen with historical controls, the primary endpoint of the trial was not met.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials in patients with limited stage SCLC that included chemoradiotherapy were terminated because of increased toxicity including tracheoesophageal fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062413\">",
"    <span class=\"h2\">",
"     Afibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    blocks the vascular endothelial growth factor (VEGF) pathway by binding to circulating VEGF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link&amp;anchor=H23212877#H23212877\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    versus topotecan was conducted in patients with sensitive and refractory SCLC. In the refractory cohort, the aflibercept arm met its primary endpoint of prolonging the three-month progression-free survival rate (27 versus 10 percent with topotecan, p = 0.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/20\">",
"     20",
"    </a>",
"    ]. The median progression-free and overall survival times were similar. The data for patients with sensitive relapse were premature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Oral angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several oral tyrosine kinase (TK) inhibitors have been evaluated in patients with SCLC to inhibit angiogenesis but none met criteria for further evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       Sorafenib",
"      </a>",
"      , a TK inhibitor of RAF and VEGF receptor, showed some activity in a multicenter, cooperative group phase II study using sorafenib as a single agent, but this was not sufficient for its continued development as a single agent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/21\">",
"       21",
"      </a>",
"      ]. Sorafenib was studied in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      in a phase II study that was halted because of a lack of efficacy and a 17 percent rate of deaths due to bleeding or neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cediranib is a potent inhibitor of VEGF receptor. In a small phase II trial conducted in patients with relapsed or refractory disease no objective responses were observed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"       Vandetanib",
"      </a>",
"      is an oral VEGF receptor and EGF receptor TK inhibitor. In a randomized phase II trial in 107 patients with an initial response to chemotherapy, maintenance therapy with vandetanib was no more effective than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/24\">",
"       24",
"      </a>",
"      ]. In a planned subgroup analyses, patients with limited-stage SCLC who received vandetanib had a significantly longer overall survival, while those with extensive-stage SCLC had a significantly shorter survival compared with placebo.",
"     </li>",
"     <li>",
"      Other small molecular antiangiogenesis inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      , BIBF1120) are also being investigated in SCLC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062575\">",
"    <span class=\"h1\">",
"     IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple immunotherapy approaches have been studied in patients with SCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tumor vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCLC expresses numerous gangliosides such as fucosyl GM1, polysialic acid, GM2, GD2 and GD3 that are not expressed on most normal tissue. These antigens have been studied as potential targets for a vaccine approach [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensively studied is the anti-idiotypic antibody (BEC-2) which mimics GD3; BEC2 was evaluated in an international phase III trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Following definitive therapy, 515 LS-SCLC responding patients were randomly assigned to BEC2 or observation. No improvement in survival was seen with the vaccine compared to observation (PFS 6.6 versus 5.7 months, and median overall survival 16.3 versus 14.3).",
"   </p>",
"   <p>",
"    Additional vaccines in clinical testing target the fucosyl GM1 ganglioside (Fuc-GM1) and polysialic acid (polySA), a component of the neural cell adhesion molecule (NCAM).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062692\">",
"    <span class=\"h2\">",
"     Ipilumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is a monoclonal antibody to CTLA-4 (cytotoxic T lymphocyte- associated antigen 4) that blocks ligand binding to CTLA-4. As a consequence T cell activation occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ipilumumab has been evaluated in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    in a randomized phase II study that included 130 patients with chemotherapy naive SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients were randomized to receive ipilumumab concurrently with chemotherapy or sequential (phased) with chemotherapy initially followed by chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    or to standard chemotherapy without ipilimumab. In the SCLC patient cohort, the phased administration of ipilumumab with chemotherapy improved progression free survival based upon immune-related response criteria (HR 0.64 95% CI 0.40-1.02;p = 0.03). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H262059967#H262059967\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Immune response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There was a trend toward prolonged overall survival in the phased treatment group that received chemotherapy followed by chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (median overall survival 12.5 versus 9.1 months for chemotherapy alone, p = 0.13). There was no significant difference between standard chemotherapy and concurrent administration of ipilumumab. A Phase III trial in which patients with ED-SCLC are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with either ipilimumab or placebo is enrolling patients (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01450761?term=NCT01450761&amp;rank=1\">",
"     NCT01450761",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other immunotherapy approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other immunotherapy approaches are also being evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunologically targeted toxins such as BB 10901, a humanized murine monoclonal antibody (huN-901) that binds to CD56 conjugated to the tubulin toxin maytansinoid cytotoxin DM1 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dentritic cells transduced with full-length wild-type p53 gene, which are delivered via an adenovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062722\">",
"    <span class=\"h1\">",
"     CYTOTOXIC CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885062730\">",
"    <span class=\"h2\">",
"     Bendamustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     Bendamustine",
"    </a>",
"    is an alkylating agent approved for the treatment of chronic lymphocytic leukemia. Bendamustine was evaluated (120",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV day 1 and 2 every 3 weeks) in relapsed SCLC after second or third line therapy. Of 33 evaluable patients 10 showed an objective response (30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;New agents are being evaluated to improve the outcome for patients with SCLC.",
"   </p>",
"   <p>",
"    None of these approaches has an established role, and these agents should be restricted to the clinical protocol setting. One reason why targeted therapies have not been successful may be due to the unselected patient populations enrolled in these studies. As the genomic characterization of SCLC continues to evolve, we are optimistic that the discovery of driver mutations will lead to successful targeted therapies for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8951/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with SCLC should be encouraged to participate in clinical trials whenever possible.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/1\">",
"      Nakanishi Y, Mulshine JL, Kasprzyk PG, et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988; 82:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/2\">",
"      Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007; 2:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/3\">",
"      Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 2011; 17:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/4\">",
"      Lee P, Alvarez RH, Melichar B, et al. Phase I/II study of the investigational aurora A kinase inhibitor (alisertib) in patients with  non-small cell lung cancer, small cell lung cancer, breast (abstract #3010). J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/5\">",
"      Schneider BJ, Kalemkerian GP, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer 2010; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/6\">",
"      Miller AA, Pang H, Hodgson L, et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 2010; 5:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/7\">",
"      Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006; 52:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/8\">",
"      Rudin CM, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/9\">",
"      Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/10\">",
"      Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/11\">",
"      Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011; 74:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/12\">",
"      Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/13\">",
"      Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/14\">",
"      Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007; 25:3945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/15\">",
"      Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009; 101:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/16\">",
"      Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011; 29:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/17\">",
"      Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27:6006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/18\">",
"      Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011; 29:4436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/19\">",
"      Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/20\">",
"      Allen JW, Moon J, Gadgeel SM, et al. SWOG 0802: A randomized phase II trial of weekly topotecan with or without AVE0005 (aflibercept) in patients with platinum treated extensive stage (abstract # 7005). J Clin Oncol 2012; 30: 453s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/21\">",
"      Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 2010; 5:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/22\">",
"      Sharma N, Pennell N, Halmos B, et al. Phase II trial of sorafenib combined with chemotherapy and as maintenance therapy in extensive stage small cell lung cancer - Final Results. J Thorac Oncol 2012; 7SS337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/23\">",
"      Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010; 5:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/24\">",
"      Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/25\">",
"      Zhang S, Cordon-Cardo C, Zhang HS, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 1997; 73:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/26\">",
"      Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23:6854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/27\">",
"      Bottomley A, Debruyne C, Felip E, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 2008; 44:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/28\">",
"      Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/29\">",
"      McCann J, Fossella FV, Villalona-Calero MA, et AL. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma (abstract). J Clin Oncol 2007; 25:690s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/30\">",
"      Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/31\">",
"      Lovly CM, Li C, Hutchinson AS, et al. A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (abstract #7094). J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8951/abstract/32\">",
"      Peifer M, Fern&aacute;ndez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44:1104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4615 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8951=[""].join("\n");
var outline_f8_47_8951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULARLY TARGETED THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IGF-1R inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885061972\">",
"      PI3K/Akt/mTOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H982488532\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885062067\">",
"      Hedgehog inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568140996\">",
"      Alisertib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568140817\">",
"      Tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885062095\">",
"      Apoptosis modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H982489764\">",
"      Other classes of molecular therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANGIOGENESIS INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885062413\">",
"      Afibercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Oral angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H885062575\">",
"      IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tumor vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885062692\">",
"      Ipilumumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other immunotherapy approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H885062722\">",
"      CYTOTOXIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H885062730\">",
"      Bendamustine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8952="Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)";
var content_f8_47_8952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8952/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8952/contributors\">",
"     Irving M Spitz, MD, DSc, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8952/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8952/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/47/8952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone is essential for the initiation and maintenance of pregnancy. After the discovery of the progesterone receptor (PR) in 1970 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/1\">",
"     1",
"    </a>",
"    ], it was realized that a progesterone receptor antagonist would have a major impact on female reproductive health. In 1981, a new glucocorticoid receptor antagonist known as RU 38486 was synthesized. It soon became evident that this antiglucocorticoid also displayed marked antiprogestin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/2\">",
"     2",
"    </a>",
"    ]. RU 38486 was subsequently abbreviated to RU 486 and is now known by the generic name",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The original studies showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    had a relative binding affinity five times that of progesterone and three times that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    at their respective receptors. When compared with testosterone, it had a relative binding affinity of 25 percent for the androgen receptor (AR) but did not bind to either estrogen or mineralocorticoid receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the discovery of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    , several hundred similar compounds have been synthesized. These compounds may display progesterone agonist, antagonist, or mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    activity. Collectively, these compounds are known as progesterone receptor modulators (PRMs).",
"   </p>",
"   <p>",
"    The chemistry, pharmacokinetics, pharmacology, metabolism, mechanism of actions, and biological effects of progesterone receptor modulators will be discussed in this topic review. Their clinical applications and adverse effects, and their use for medical termination of pregnancy and emergency contraception are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=see_link\">",
"     \"Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link&amp;anchor=H10#H10\">",
"     \"Emergency contraception\", section on 'Antiprogestins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92161842\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this topic, progesterone receptor agonists are referred to as PAs and those compounds with mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    activity are referred to as selective progesterone receptor modulators (SPRMs). Collectively, these compounds are known as progesterone receptor modulators (PRMs) (",
"    <a class=\"graphic graphic_figure graphicRef55707 \" href=\"UTD.htm?27/62/28654\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The term SPRM is in keeping with the terminology adapted for selective estrogen receptor modulators (SERMs). From a pharmacological, biochemical, and clinical perspective, a SPRM represents a class of progesterone receptor ligands that exerts clinically relevant, tissue selective, mixed progesterone agonist and antagonist effects, which may be full or partial, on various progesterone target tissues in an in vivo situation depending on the biological action studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    is similar in structure to progesterone and glucocorticoids, but lacks the C19-methyl group and the 2-carbon side chain at C17 and has a conjugated C9-C10 double bond (",
"    <a class=\"graphic graphic_figure graphicRef80074 \" href=\"UTD.htm?26/8/26767\">",
"     figure 2",
"    </a>",
"    ). It is a derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    with a 4-dimethylamino phenyl group at the 11-beta position. This is responsible for its antagonistic activity. The 1-propynyl chain at the 17-alpha position accounts for its high binding affinity to the progesterone receptor (PR) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are other PRMs that are now available, or are being evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. CDB-2914, a selective progesterone receptor modulator with primarily antiprogestin activity, is available worldwide for emergency contraception. When used for emergency contraception, it is referred to as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     ulipristal",
"    </a>",
"    acetate, and in the US, is marketed under the name ella&reg;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link&amp;anchor=H11#H11\">",
"     \"Emergency contraception\", section on 'Ulipristal'",
"    </a>",
"    .) This antiprogestin, CDB-2914 (ulipristal acetate), is being studied for other indications as well, such as the treatment of fibroids. Another compound, J 867, asoprisnil, is also being studied for a potential therapy for uterine fibroids (",
"    <a class=\"graphic graphic_figure graphicRef80074 \" href=\"UTD.htm?26/8/26767\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS, PHARMACOLOGY, AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    is administered orally. The drug has a bioavailability ranging from 30 to 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/14\">",
"     14",
"    </a>",
"    ]. It binds with high affinity to orosomucoid, an alpha-1 acid glycoprotein, and weakly to albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Serum concentrations reach a peak one hour after administration of single doses ranging from 2 to 800 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the oral dose administered, two distinct pharmacokinetic patterns are seen. After single doses of 100 mg or less, the disappearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    follows first-order kinetics with a half-life of 20 to 25 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/15\">",
"     15",
"    </a>",
"    ]. Following higher doses (200 to 800 mg), there is an initial redistribution phase of 6 to 10 hours followed by zero-order kinetics and a plateau in serum concentrations for 24 hours or more. With these larger doses, there is no significant dose-dependent difference in serum concentrations within the first 48 hours (",
"    <a class=\"graphic graphic_figure graphicRef50232 \" href=\"UTD.htm?32/17/33054\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. One of the possible explanations for this unusual pattern of metabolism is that orosomucoid binding sites are saturated at doses of mifepristone above 100 mg.",
"   </p>",
"   <p>",
"    The major excretory pathway for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    is fecal, with less than 10 percent being recovered in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/16\">",
"     16",
"    </a>",
"    ]. The first steps of mifepristone metabolism involve a two-step demethylation of the (dimethylamino)phenyl ring at the C11 position and hydroxylation of the 17-propynyl chain. The demethylated metabolites are further hydroxylated or acetylated (",
"    <a class=\"graphic graphic_figure graphicRef64721 \" href=\"UTD.htm?31/60/32718\">",
"     figure 4",
"    </a>",
"    ). The oxidation of mifepristone to its three principal metabolites is catalyzed by cytochrome P450 3A4 (CYP3A4) in the liver. This member of the 3A subfamily belongs to the CYP superfamily of hemoproteins that catalyze the oxidative metabolism of a large number of drugs in man. The interaction of mifepristone with CYP3A4 (as substrates, inactivators, and potential inducers of the enzyme) may influence the pharmacokinetic characteristics of other drugs metabolized by CYP3A4. This is likely to occur with multiple-dose or long-term use and clearly has important clinical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, drugs that are metabolized by CYP 3A4 may result in either an increase or decrease in serum mifepristone concentrations.",
"   </p>",
"   <p>",
"    In the human, micromolar concentrations of the monodemethylated, didemethylated, and the non-demethylated hydroxylated (alcoholic) metabolites of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    are detected within one hour after oral administration of mifepristone. In contrast to the parent compound, serum concentrations of metabolites increase in a dose-dependent fashion and with higher doses, the metabolite concentrations, especially the monodemethylated derivative, are in excess of the parent compound (",
"    <a class=\"graphic graphic_figure graphicRef76374 \" href=\"UTD.htm?11/14/11503\">",
"     figure 5",
"    </a>",
"    ). These metabolites bind to the human progesterone and glucocorticoid receptors. Even though the affinity and effectiveness is less than that of mifepristone, these metabolites may contribute to the overall effects of the drug in view of their high concentrations in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CDB-2914 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"     ulipristal",
"    </a>",
"    acetate), a compound that is used worldwide for emergency contraception, is rapidly absorbed after an oral dose and is detectable in the blood within 15 minutes, reaching peak serum levels by 60 to 90 minutes. The subsequent slow rate of clearance was likely due to binding of CDB-2914 to serum proteins, including orosomucoid, albumin, globulins, and cholesterol binding proteins. The lower doses of CDB-2914 (1, 10, and 50 mg) had peak serum levels that were proportional to dose. Doses higher than 50 mg did not produce proportionately higher peak serum levels, indicating that saturation of some component must come into play at higher oral doses. Serum levels of CDB-2914 were still detectable by radioimmunoassay at five days with doses of 10 mg or above. The radioimmunoassay that is used to measure CDB-2914 in serum cross-reacts extensively with the putative mono- and didemethylated derivatives of CDB-2914. These derivatives also bind to progesterone receptors and appear to be biologically active in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the administration of the 12.5, 25, and 50 mg, CDB-4124, plasma concentration profiles showed a biphasic decay pattern. CDB-4124 was rapidly absorbed, reaching peak plasma levels in 0.5 to 2 hours. The mean apparent half-life values of CDB-4124 ranged from 8.3 to 18.8 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metabolism of asoprisnil has been studied using rat, guinea pig, and monkey hepatocytes and liver microsomes. Although there are quantitative differences in the metabolites detected in each model system, their profiles are qualitatively similar. Asoprisnil is metabolized primarily to J912, the O-demethylated form. Asoprisnil and its O-demethylated metabolites may also undergo conjugation with glutathione. Purified J912 shows agonistic and antagonistic effects in the rabbit uterus, and has marginal labor-inducing properties in the guinea pig model [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary action of progesterone is to initiate and maintain pregnancy. During pregnancy, progesterone inhibits myometrial contractility and maintains the uterus in a quiescent state. Additional actions of progesterone include its facilitation of the luteinizing hormone (LH) surge and transformation of the endometrium from a proliferative to a secretory state. Together with estradiol, progesterone also maintains endometrial integrity. The decrease of these steroids at the end of the luteal phase is responsible for menstrual bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The actions of progesterone as well as PAs and SPRMs in target tissues are mediated by the PR that belongs to a family of nuclear receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This family includes receptors not only for the steroid hormones (glucocorticoid, mineralocorticoid, androgen, estrogen, and vitamin D) but also for the thyroid hormones and the retinoids. These receptors are ligand-activated transcription factors with domains for DNA binding, hormone binding, and transactivation. Following binding of progesterone (or progestins), PAs, and SPRMs to the ligand-binding domain of the PR, there is an alteration in its conformation; it undergoes dimerization, which converts it from a non-DNA binding form to one which will bind DNA. The dimerized receptor then binds to progesterone response elements (PREs) located in the promoter region of target genes. In the presence of progesterone or a pure progesterone agonist (",
"    <a class=\"graphic graphic_figure graphicRef60380 \" href=\"UTD.htm?19/13/19666\">",
"     figure 6",
"    </a>",
"    ), there is interaction with coactivators, which form a multi-protein complex that activates the general transcriptional machinery and increases the expression of target genes through various processes which include nuclear receptor and coregulator phosphorylation, regulation of coregulator function by ubiquitinylation or sumoylation, and coactivator methylation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the presence of a PA, receptors adopt an inactive conformation and preferentially interact with corepressors, resulting in loss of transcriptional activity (",
"    <a class=\"graphic graphic_figure graphicRef70217 \" href=\"UTD.htm?4/52/4928\">",
"     figure 7",
"    </a>",
"    ). The mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    asoprisnil partially recruits coactivators and strongly recruits corepressors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/23\">",
"     23",
"    </a>",
"    ]. This explains its mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    action. The biological response thus depends in part on the relative expression of coactivators and corepressors in a given cell environment (",
"    <a class=\"graphic graphic_figure graphicRef77646 \" href=\"UTD.htm?31/4/31823\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BIOLOGICAL ACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike progesterone, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    -PR complex inhibits transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and if implantation has occurred, this results in down-regulation of progesterone-dependent genes with decidual necrosis and detachment of products of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/4\">",
"     4",
"    </a>",
"    ]. Mifepristone also acts on endometrial blood vessels, causing vascular damage that further compromises the embryo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/24\">",
"     24",
"    </a>",
"    ]. It also directly promotes uterine contractions by increasing myometrial-cell excitability establishing gap junctions between cells and influx of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    increases the myometrial response and sensitivity to exogenous prostaglandins, which further increases uterine contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/26\">",
"     26",
"    </a>",
"    ]. It also increases the release of prostaglandins by decidual cells and induces an accumulation of prostaglandins by inhibiting prostaglandin dehydrogenase, the progesterone-dependent enzyme, which metabolizes the active prostaglandins, PGE2 and PGF2alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a pregnant guinea pig model, topical administration of cytokines, IL-8, IL-1b, and a nitric oxide (NO) donor, induced cervical ripening [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Progesterone inhibits IL-8 release in human choriodecidual cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/31\">",
"     31",
"    </a>",
"    ] and suppresses NO production [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    stimulates IL-8 release, NO release, and the expression of iNOS (inducible nitric oxide synthase) in the human cervix, suggesting that this is the mechanism whereby mifepristone initiates cervical ripening [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the presence of coactivators or corepressors, the biological response to a ligand also depends on the species studied, the prevailing steroid milieu, the dose of drug, the target tissue examined, and whether the experiments were conducted under in vivo or in vitro conditions. Difficulties are compounded by the lack of uniformity as to which biological response to evaluate. The time-honored test described by McPhail in 1935 remains the most effective in vivo method available of determining progesterone biological activity and ascertaining if a compound is a pure progesterone agonist, antagonist, or mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist.",
"    </span>",
"    This is based on the degree of progestational activity in an estrogen-primed immature rabbit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/35\">",
"     35",
"    </a>",
"    ]. In this model, progesterone behaves as a pure agonist and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    as a pure antagonist. In contrast, the J compounds (including asoprisnil, J956 and J1042) behave as true mixed agonist-antagonists. Importantly, in the McPhail model, these J compounds, even in high doses, do not display as potent an agonist activity as progesterone nor as potent an antagonist effect as mifepristone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/12\">",
"     12",
"    </a>",
"    ]. They thus fulfill the clinical definition of a SPRM with mixed agonist-antagonist activity (",
"    <a class=\"graphic graphic_figure graphicRef63978 \" href=\"UTD.htm?30/57/31633\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ENDOMETRIAL EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of PAs or SPRMs is associated with a reduction of menstrual bleeding or even amenorrhea. Proposed mechanisms for the amenorrhea include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppression of estrogen-dependent endometrial proliferation and mitotic activity, secretory activity, and reduced endometrial thickness and wet weight [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]. Since most SPRMs and PAs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      , bind minimally if at all to the estrogen receptor, this antiproliferative endometrial effect has been described as non-competitive or functional [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/36\">",
"       36",
"      </a>",
"      ]. It is selective and is not observed in bone or in the oviduct [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/38,40\">",
"       38,40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antiproliferative actions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The amenorrhea could also be due to direct effects on endometrial vasculature.",
"     </li>",
"     <li>",
"      Low doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      (2 or 5 mg daily) up-regulate glucocorticoid receptors in the endometrial glandular nuclei and surface (luminal) epithelium and reduce stromal vascular endothelial growth factor (VEGF) protein expression [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Daily doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      (2 to 5 mg), CDB-4124 (12.5 to 50 mg), and CDB-2914 (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39412?source=see_link\">",
"       ulipristal",
"      </a>",
"      acetate 5 to 10 mg) inhibit ovulation in normal women and this may contribute to the amenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. In contrast, asoprisnil is less effective in inhibiting ovulation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antiproliferative actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the effects of PAs, which are the expected consequences of progesterone antagonism, many PAs and SPRMs display antiproliferative effects. These are mainly seen in a primate model and are thought to be related to a number of possible mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in estrogen receptor (ER) and progesterone receptor (PR) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/45\">",
"       45",
"      </a>",
"      ], suggesting that the endometrial effect is due to progesterone antagonism.",
"     </li>",
"     <li>",
"      An increase in androgen receptor (AR) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/46\">",
"       46",
"      </a>",
"      ]. Androgens suppress estrogen-induced endometrial proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/47\">",
"       47",
"      </a>",
"      ]. The pure antiandrogen,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      , blocks the antiproliferative effects of the PAs ZK137316 and ZK230211 in the endometrium [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/48\">",
"       48",
"      </a>",
"      ]. Flutamide also blocks the hyalinizing degeneration of the spiral arteries induced by PAs [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/48\">",
"       48",
"      </a>",
"      ]. This effect on the AR appears to be the most likely mechanism for the antiproliferative effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antiproliferative effect may also be related to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PR-A isoform inhibits estrogen receptor gene transcription induced by progestins and PAs [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced endometrial blood supply due to atrophy of spiral arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blockade of progesterone-dependent growth factors such as keratinocyte growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of angiogenesis via suppression of beta fibroblast growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/53\">",
"       53",
"      </a>",
"      ] or vascular endothelial growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/54\">",
"       54",
"      </a>",
"      ] and cell cycle block at G2-M interphase [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antioxidant properties [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       Mifepristone",
"      </a>",
"      promotes apoptosis by overexpressing bax and down-regulating bcl-2 in human endometrial cells and endometrial adenocarcinoma cells [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progesterone has dual actions on fibroid growth. It stimulates growth by upregulating EGF and Bcl-2 and down-regulating TNFa expression. It inhibits growth by down-regulating IGF-I expression. PRMs suppress fibroid growth, but their mechanisms vary and are compound-specific [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8952/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone receptor agonists, progesterone receptor antagonists (PAs), and selective progesterone receptor modulators (SPRMs) are compounds that display progesterone agonist, antagonist, or mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    activity, respectively.",
"   </p>",
"   <p>",
"    The mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    properties and tissue-selective effects of SPRMs can be explained by a special conformation of the receptor induced by a SPRM that allows partial interaction with coactivators and corepressors. Thus, based upon its mechanism of action, a SPRM differs from a PA or an agonist.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/1\">",
"      Sherman MR, Corvol PL, O'Malley BW. Progesterone-binding components of chick oviduct. I. Preliminary characterization of cytoplasmic components. J Biol Chem 1970; 245:6085.",
"     </a>",
"    </li>",
"    <li>",
"     Philibert D. RU38486: An original multifaceted antihormone in vivo. In: Adrenal Steroid Antagonism, Agarwal MK (Ed), W. de Gruyter, Berlin 1984. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/3\">",
"      Baulieu EE. Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 1989; 245:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/4\">",
"      Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/5\">",
"      Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 1996; 36:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/6\">",
"      Wiechert R, Neef G. Synthesis of antiprogestational steroids. J Steroid Biochem 1987; 27:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/7\">",
"      Fuhrmann U, Hess-Stumpp H, Cleve A, et al. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem 2000; 43:5010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/8\">",
"      Slayden OD, Chwalisz K, Brenner RM. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod 2001; 16:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/9\">",
"      Heikinheimo O, Vani S, Carp&eacute;n O, et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum Reprod 2007; 22:2515.",
"     </a>",
"    </li>",
"    <li>",
"     Wiehle RD, Goldberg J, Brodniewicz T, et al. Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet Gynecol 2008; 3:17. file://www.touchbriefings.com/ebooks/A18oyx/usobsvol3iss1/resources/18.htm (Accessed on April 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/11\">",
"      DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003; 68:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/12\">",
"      Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000; 65:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/13\">",
"      Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/14\">",
"      Jang GR, Benet LZ. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm 1997; 25:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/15\">",
"      L&auml;hteenm&auml;ki P, Heikinheimo O, Croxatto H, et al. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 1987; 27:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/16\">",
"      Robbins A, Spitz IM. Mifepristone: clinical pharmacology. Clin Obstet Gynecol 1996; 39:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/17\">",
"      Kekkonen R, Heikinheimo O, Mandelin E, L&auml;hteenm&auml;ki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 1996; 54:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/18\">",
"      Blithe DL, Nieman LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003; 68:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/19\">",
"      Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003; 68:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/20\">",
"      Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999; 54:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/21\">",
"      Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood) 2002; 227:969.",
"     </a>",
"    </li>",
"    <li>",
"     Smith, CL, O'Malley, BW. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004. 25:45.",
"    </li>",
"    <li>",
"     Bray, JD, Grygielko, et al. Asoprisnil, a selective progesterone receptor modulator, displays a distinct profile in PR-mediated assays, and the ability to recruit both coactivators and corepressors may explain its failure to demonstrate antiestrogenic activity on eutopic and ectopic rat uterine tissue. Endocrine Society Meeting, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/24\">",
"      Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception 1989; 39:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/25\">",
"      Garfield RE, Blennerhassett MG, Miller SM. Control of myometrial contractility: role and regulation of gap junctions. Oxf Rev Reprod Biol 1988; 10:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/26\">",
"      Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/27\">",
"      Cheng, L, et al. The effect of mifepristone (RU486) on the immunohistochemical distribution of prostaglandin E and its metabolite in decidual and chorionic tissue in early pregnancy. J Clin Endocrinol Metab, 1993; 77:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/28\">",
"      Cheng L, Kelly RW, Thong KJ, et al. The effects of mifepristone (RU486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum Reprod 1993; 8:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/29\">",
"      Chwalisz K, Benson M, Scholz P, et al. Cervical ripening with the cytokines interleukin 8, interleukin 1 beta and tumour necrosis factor alpha in guinea-pigs. Hum Reprod 1994; 9:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/30\">",
"      Chwalisz K, Shao-Qing S, Garfield RE, Beier HM. Cervical ripening in guinea-pigs after a local application of nitric oxide. Hum Reprod 1997; 12:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/31\">",
"      Kelly RW, Leask R, Calder AA. Choriodecidual production of interleukin-8 and mechanism of parturition. Lancet 1992; 339:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/32\">",
"      Chwalisz K, St&ouml;ckemann K, Fritzemeier KH, Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum Reprod Update 1998; 4:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/33\">",
"      Chwalisz K, Garfield RE. Nitric oxide as the final metabolic mediator of cervical ripening. Hum Reprod 1998; 13:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/34\">",
"      V&auml;is&auml;nen-Tommiska M, Butzow R, Ylikorkala O, Mikkola TS. Mifepristone-induced nitric oxide release and expression of nitric oxide synthases in the human cervix during early pregnancy. Hum Reprod 2006; 21:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/35\">",
"      McPhail MK. The assay of progestin. J Physiol 1934; 83:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/36\">",
"      Hodgen GD, van Uem JF, Chillik CF, et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 1994; 9 Suppl 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/37\">",
"      Slayden OD, Zelinski-Wooten MB, Chwalisz K, et al. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998; 13:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/38\">",
"      Slayden OD, Brenner RM. RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 1994; 78:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/39\">",
"      Baird DT, Brown A, Critchley HO, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/40\">",
"      Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996; 81:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/41\">",
"      Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod 2006; 21:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/42\">",
"      Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P, VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92:3582.",
"     </a>",
"    </li>",
"    <li>",
"     Spitz IM. Progesterone receptor antagonists. In: Nuclear receptors as drug targets, Ottow E, Weinmann H (Eds), WILEY-VCH, Weinheim, Germany 2008. Vol 39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/44\">",
"      Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005; 20:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/45\">",
"      Neulen J, Williams RF, Breckwoldt M, et al. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Hum Reprod 1996; 11:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/46\">",
"      Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 2002; 124:167.",
"     </a>",
"    </li>",
"    <li>",
"     Slayden, OD, Carroll, R, et al. Exogenous androgen blocks endometrial growth in primates: relevance to the antiproliferative effects of progesterone antagonists. SGI 53rd Annual Meeting, Toronto, Ontario, Canada, Elsevier.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/48\">",
"      Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 2003; 88:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/49\">",
"      McDonnell DP, Goldman ME. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem 1994; 269:11945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/50\">",
"      Zelinski-Wooten MB, Slayden OD, Chwalisz K, et al. Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity. Hum Reprod 1998; 13:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/51\">",
"      Chwalisz K, Brenner RM, Fuhrmann UU, et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000; 65:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/52\">",
"      Koji T, Chedid M, Rubin JS, et al. Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. J Cell Biol 1994; 125:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/53\">",
"      Grow DR, Reece MT, Hsiu JG, et al. Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Fertil Steril 1998; 69:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/54\">",
"      Greb RR, Heikinheimo O, Williams RF, et al. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum Reprod 1997; 12:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/55\">",
"      Heikinheimo O, Hsiu JG, Gordon K, et al. Endometrial effects of RU486 in primates--antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J Steroid Biochem Mol Biol 1996; 59:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/56\">",
"      Parthasarathy S, Morales AJ, Murphy AA. Antioxidant: a new role for RU-486 and related compounds. J Clin Invest 1994; 94:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/57\">",
"      Han S, Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 2003; 88:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/58\">",
"      Ohara N, Morikawa A, Chen W, et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 2007; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     Ohara N, Xu Q, Matsuo H, Maruo T. Progesterone and progesterone receptor modulator in uterine leiomyoma growth. In: Translational research in uterine biology, Maruo T, Mardon H, Stewart C (Eds), Elsevier, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8952/abstract/60\">",
"      Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7420 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8952=[""].join("\n");
var outline_f8_47_8952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92161842\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS, PHARMACOLOGY, AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BIOLOGICAL ACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ENDOMETRIAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antiproliferative actions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7420|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/62/28654\" title=\"figure 1\">",
"      Progestagenic biological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/8/26767\" title=\"figure 2\">",
"      Chem composition PA and PRM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/17/33054\" title=\"figure 3\">",
"      Mifepristone over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/60/32718\" title=\"figure 4\">",
"      Metabolism of mifepristone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11503\" title=\"figure 5\">",
"      mifepristone monodemethyla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/13/19666\" title=\"figure 6\">",
"      Prog activation of PR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/52/4928\" title=\"figure 7\">",
"      Action of prog antags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/4/31823\" title=\"figure 8\">",
"      SPRM coact corepress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/57/31633\" title=\"figure 9\">",
"      Pharm prog antags and SPRMs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=related_link\">",
"      Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8953="Blunt cerebrovascular injury: Treatment and outcomes";
var content_f8_47_8953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blunt cerebrovascular injury: Treatment and outcomes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Walter L. Biffl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Clay Cothren Burlew, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Ernest E Moore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8953/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/47/8953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H273294\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt carotid and vertebral artery injuries, collectively termed blunt cerebrovascular injury, are rare but potentially devastating events. The incidence of blunt cerebrovascular injury in patients sustaining blunt trauma is about 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Blunt carotid injury is associated with mortality rates that range from 23 to 28 percent, with 48 to 58 percent of survivors suffering permanent severe neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the high morbidity and mortality rates associated with blunt cerebrovascular injury, conservative management is not appropriate unless there are contraindications to treatment. Treatment strategies include antithrombotic therapy, surgical repair, and endovascular intervention. The treatment strategy for a given individual depends upon their symptoms, site of injury, severity or grade of injury and associated injuries that may complicate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and outcomes of blunt cerebrovascular injury will be reviewed here. The injury mechanisms, screening, and diagnosis of blunt cerebrovascular injury are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=see_link\">",
"     \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Penetrating cerebrovascular injury and spontaneous cerebrovascular dissection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link\">",
"     \"Penetrating neck injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link\">",
"     \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280052\">",
"    <span class=\"h1\">",
"     INJURY GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A grading scale for blunt cerebrovascular injury was created to standardize clinical communication and to guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6\">",
"     6",
"    </a>",
"    ]. For the carotid artery, stroke rates increase with increasing injury grade [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6\">",
"     6",
"    </a>",
"    ]. Stroke incidence and neurologic outcome for vertebral injury are independent of injury grade. In a study of 171 patients found to have 236 blunt cerebrovascular injuries, the distribution of injury is representative: grade I (58 percent), grade II (22 percent), grade III (14 percent), grade IV (11 percent), and grade V (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The injury grades given below apply to carotid or vertebral artery lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I: Intimal irregularity or dissection with &lt;25 percent luminal narrowing.",
"     </li>",
"     <li>",
"      Grade II: Dissection or intramural hematomas with &ge;25 percent luminal narrowing, intraluminal clot, or a visible intimal flap. &nbsp;",
"     </li>",
"     <li>",
"      Grade III: Pseudoaneurysm or hemodynamically insignificant arteriovenous fistula.",
"     </li>",
"     <li>",
"      Grade IV: Complete occlusion. A small number may undergo recanalization.",
"     </li>",
"     <li>",
"      Grade V: Transection with active extravasation (hemorrhage) or hemodynamically significant arteriovenous fistula. These injuries are often lethal. Transection injuries mandate immediate attempts to control bleeding. (See",
"      <a class=\"local\" href=\"#H785734511\">",
"       'Other interventions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259192\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the incidence of blunt cerebrovascular injury is very low and experience with this problem is limited, even in busy trauma centers, no controlled trials are available to help guide management. Treatment is based upon the demonstration of reduced neurologic and other morbidity and mortality in treated patients compared with those who are untreated (and to historical controls), from indirect evidence derived from the penetrating neck injury literature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/8\">",
"     8",
"    </a>",
"    ], and from strategies used in the management of non-traumatic cerebrovascular disorders (eg, spontaneous cerebrovascular dissection). Our treatment recommendations are in general agreement with protocols established by major trauma societies (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mainstay of treatment is antithrombotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , or antiplatelet therapy) but the optimal regimen is not known with respect to agent, duration of treatment or end-point of therapy. Associated injuries often contraindicate antithrombotic therapy. Other treatment options include surgical intervention (accessible lesions) or endovascular intervention. Factors that determine the treatment strategy for a specific individual include symptoms, site of injury, severity or grade of injury and associated injuries that may contraindicate a specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6\">",
"     6",
"    </a>",
"    ]. The rationale and recommendations for antithrombotic therapy or other intervention, follow-up and injury grade-specific recommendations are discussed below. (See",
"    <a class=\"local\" href=\"#H785733443\">",
"     'Antithrombotic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H785734511\">",
"     'Other interventions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H259255\">",
"     'Follow-up for healing or progression'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H785740622\">",
"     'Injury grade-specific recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785733443\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend antithrombotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or antiplatelet therapy) for all patients with blunt cerebrovascular injury who do not have contraindications (eg, active hemorrhage [grade V]) from the vessel. (See",
"    <a class=\"local\" href=\"#H785740391\">",
"     'Contraindications to antithrombotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The rationale for using antithrombotic therapy for blunt cerebrovascular injury is based upon reduced rates of neurologic morbidity and mortality identified in retrospective reviews of anticoagulated patients or those treated with antiplatelet agents compared with untreated patients with treatment contraindications or historic, untreated controls, for whom stroke rates are typically 50 percent or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7,9-19\">",
"     7,9-19",
"    </a>",
"    ]. In studies that reflect the use of antithrombotic therapies, overall stroke rates for blunt injury (all grades) of the internal carotid artery, common carotid artery, and vertebral injuries are 26 to 41 percent, 11 percent, and 14 to 24 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/4,7,17\">",
"     4,7,17",
"    </a>",
"    ]. Stroke rates increase with increasing injury grade for carotid but not vertebral artery injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one study, stroke rates for 114 blunt carotid and 79 blunt vertebral injuries were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I: carotid 8 percent; vertebral 6 percent",
"     </li>",
"     <li>",
"      Grade II: carotid 14 percent; vertebral 38 percent",
"     </li>",
"     <li>",
"      Grade III: carotid 26 percent; vertebral 27 percent",
"     </li>",
"     <li>",
"      Grade IV: carotid 50 percent; vertebral 28 percent",
"     </li>",
"     <li>",
"      Grade V: carotid 100 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple retrospective studies have found improved neurologic outcomes among symptomatic patients, and fewer ischemic neurologic events (stroke) in asymptomatic patients with blunt cerebrovascular injury who are heparinized compared with those who are not [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7,12,15,17,18,20,21\">",
"     7,12,15,17,18,20,21",
"    </a>",
"    ]. Injury-specific mortality rates are also reduced. However, patients who are not treated are usually sicker, with several contraindications to treatment, such as head injury, which influences the comparison. The largest of these studies are summarized below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large retrospective review, arteriography was used to screen 727 of 15,767 blunt-trauma patients at high risk for blunt cerebrovascular injury, which was identified in 244 of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/14\">",
"       14",
"      </a>",
"      ]. Antithrombotic therapy was initiated in 187 asymptomatic patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (n = 117), low molecular-weight heparin (n = 11), and antiplatelet agents (n = 59). Asymptomatic patients who were treated with antithrombotic therapy had a lower ischemic neurologic event rate compared with 48 patients who were not able to be anticoagulated (0.5 versus 21 percent).",
"     </li>",
"     <li>",
"      A retrospective trauma registry review identified 139 blunt cerebrovascular injuries in 96 patients, 75 involving the carotid arteries (14 bilateral), 64 involving the vertebral arteries (14 bilateral), and 15 patients with both [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/17\">",
"       17",
"      </a>",
"      ]. Antithrombotic therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , antiplatelet therapy) was used to treat 43 of 75 carotid injuries and 39 of 50 vertebral artery injuries. Stroke rates for treated and untreated patients were 6.8 versus 64 percent for carotid artery injury, and 2.6 versus 54 percent for vertebral artery injury.",
"     </li>",
"     <li>",
"      Blunt carotid artery injury was identified in 114 patients screened out of 643 patients at risk from 13,280 blunt trauma admissions [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/18\">",
"       18",
"      </a>",
"      ]. None of 73 patients treated with antithrombotic therapy suffered a stroke, whereas 46 percent of the 41 patients who did not receive anticoagulation developed ischemic neurologic events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785733542\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In agreement with major society trauma guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ), we suggest initiating antithrombotic therapy in patients with blunt cerebrovascular injury with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    We administer heparin as a weight-based infusion of 15",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour (no bolus), to achieve an activated partial thromboplastin time (aPTT) of 40 to 50 seconds (lower target range compared with other indications). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the acute setting because it is reversible (many of these patients will require surgery for unrelated injuries) and may be more effective than antiplatelet drugs. There are no randomized trials directly comparing heparin with antiplatelet therapy in the management of blunt cerebrovascular injury; however, a few small retrospective case series and reports from two large trauma centers suggest that antiplatelet therapy may be at least as effective as systemic heparinization for stroke prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7,13,19,22-24\">",
"     7,13,19,22-24",
"    </a>",
"    ]. Key results are summarized below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 114 patients with blunt cerebrovascular injury found no significant differences in healing or in progression of injury grade whether the patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (n = 45) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (n = 24) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"       7",
"      </a>",
"      ]. Among the 45 patients who had ischemic neurologic symptoms attributable to the injury, treatment with heparin (n = 31) improved the patient&rsquo;s neurologic status in a greater percentage of patients (71 versus 60 percent) compared with patients treated with aspirin (n = 5) but the difference was not significant.",
"     </li>",
"     <li>",
"      In a study of 422 patients with blunt cerebrovascular injury (some overlap with the study above),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (n = 192),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (n = 67) or aspirin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (n = 23) were used to treat 192 asymptomatic patients; 107 patients were untreated [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/13\">",
"       13",
"      </a>",
"      ]. There were no significant differences in injury healing (39, 43, 46 percent) or progression of injury grade (12, 10, 15 percent) between the treatment groups. A single stroke (0.5 percent) occurred among patients who were treated (heparin group) compared with a stroke rate of 21 percent in the untreated group.",
"     </li>",
"     <li>",
"      A prospective study identified 22 patients with blunt carotid injury over an eight year follow-up period [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/24\">",
"       24",
"      </a>",
"      ]. Of these, eight patients received no treatment, seven patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , and seven with antiplatelet therapy. No differences in neurologic outcomes were observed between anticoagulated patients and those receiving antiplatelet therapy. Bleeding complications were higher in patients treated with heparin compared with antiplatelet therapy with four of the anticoagulated patients suffering major bleeding complications that required cessation of heparin and blood transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who have contraindications to anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , we use antiplatelet agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    75-325 mg daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 mg daily). (See",
"    <a class=\"local\" href=\"#H785740391\">",
"     'Contraindications to antithrombotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although dual antiplatelet therapy may be indicated for other conditions, we do not use dual antiplatelet therapy in patients with blunt cerebrovascular injury due to an increased risk of bleeding and undemonstrated benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For long-term anticoagulation, a transition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has been used in the past, but antiplatelet therapy may be preferable to warfarin in the long-term due to its potential equivalent efficacy (as discussed above), better safety profile, and lower cost [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H259255\">",
"     'Follow-up for healing or progression'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H785740622\">",
"     'Injury grade-specific recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785733569\">",
"    <span class=\"h3\">",
"     Monitoring and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with antithrombotic therapy should be closely monitored for bleeding complications, which can be serious. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H21#H21\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pre-existing abnormalities in coagulation increase the risk of bleeding in the injured population. Treatment of multiply-injured and brain-injured patients may be compounded by trauma-induced coagulopathy that further increases the risk for hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link\">",
"     \"Coagulopathy associated with trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link&amp;anchor=H7527255#H7527255\">",
"     \"Management of acute severe traumatic brain injury\", section on 'Hemostatic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extracranial hemorrhage is a frequent complication of anticoagulation in patients with multiple injuries. One study noted that bleeding requiring either transfusion or cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    occurred in 54 percent of patients treated with heparin when administering a bolus dose or titrating to a standard activated partial thromboplastin time (aPTT) goal of 60 to 80 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/5\">",
"     5",
"    </a>",
"    ]. A more conservative protocol for initiation (no bolus) and maintenance of heparin infusion (aPTT 40-50) should be used in any injured patient at risk for bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H785733542\">",
"     'Choice of agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740391\">",
"    <span class=\"h3\">",
"     Contraindications to antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-third of patients are not candidates for antithrombotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/26\">",
"     26",
"    </a>",
"    ]. Contraindications to antithrombotic therapy in patients with blunt cerebrovascular injury are often related to associated injuries (eg, bleeding pelvic fracture). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=see_link&amp;anchor=H219286132#H219286132\">",
"     \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\", section on 'Associated injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785734511\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature of symptoms, injury location, and specific type (grade) of injury may indicate the need for other interventions in addition to antithrombotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785732816\">",
"    <span class=\"h3\">",
"     Surgery for accessible lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without completed hemiplegic deficits, we suggest surgical management for patients with surgically accessible Grade II through Grade V blunt cerebrovascular injuries, in agreement with major trauma society guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, many blunt cerebrovascular injuries involve the vessel (eg, internal carotid artery) at the base of the skull, and are therefore",
"    <strong>",
"     not",
"    </strong>",
"    surgically accessible. In our experience, only 2 of 700 patients treated with blunt cerebrovascular injury had a surgically-accessible lesion. This experience is shared by others. Thus, inaccessibility precludes direct surgical repair in most patients with blunt cerebrovascular injury.",
"   </p>",
"   <p>",
"    Indirect evidence of benefit for this approach comes from observational studies of patients with penetrating cerebrovascular injury, which have found lower rates of neurologic morbidity and mortality for patients undergoing neck exploration and vascular repair compared with nonoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/2,8,27-31\">",
"     2,8,27-31",
"    </a>",
"    ]. In retrospective studies that compared carotid artery repair to carotid artery ligation, patients with minimal neurologic deficits did much better with repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/4,32-34\">",
"     4,32-34",
"    </a>",
"    ]. However, these results may not necessarily extrapolate to all patients with blunt cerebrovascular injury.",
"   </p>",
"   <p>",
"    Similar to penetrating injury, a number of studies performed prior to the more frequent use of anticoagulation and endovascular techniques, found that patients with blunt cerebrovascular injury who had minimal or no symptoms and an accessible carotid lesion, did well with operative intervention (debridement, repair) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/2-4,27\">",
"     2-4,27",
"    </a>",
"    ]. As an example, one study reported a mortality of 8 percent for patients undergoing repair compared with 50 percent for those undergoing ligation and patients who did not have a deficit before surgery were not likely to develop a deficit if the vessel was repaired [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/33\">",
"     33",
"    </a>",
"    ]. However, patients with profound neurologic deficits on presentation are not likely to have any improvement.",
"   </p>",
"   <p>",
"    Extracranial-intracranial bypass has been successfully employed in selected patients, but the use of this procedure for this indication is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785732723\">",
"    <span class=\"h3\">",
"     Endovascular therapy for inaccessible lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that most blunt cerebrovascular injuries are surgically inaccessible, endovascular therapy may provide a treatment option for certain injuries, in addition to antithrombotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6,7,9,10\">",
"     6,7,9,10",
"    </a>",
"    ]. Many small series and case reports have used endovascular interventions for various types of blunt cerebrovascular injury, but there have been no controlled trials, and clear indications for endovascular therapy have yet to be developed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/30,36-40\">",
"     30,36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some groups have reported a good safety and patency with endovascular intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/19,41-43\">",
"     19,41-43",
"    </a>",
"    ]; however, the risks of endovascular treatment may exceed the benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/44\">",
"     44",
"    </a>",
"    ]. One study found a 17 percent incidence of stent-related complications and a 45 percent occlusion rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/44\">",
"     44",
"    </a>",
"    ]. The carotid artery occlusion rate was higher in patients who underwent stenting compared with patients who were treated with antithrombotic agents alone (21 versus 5 percent). It is clear that caution is needed, when endovascular therapy is chosen, to avoid dislodging debris during stent deployment, and post-stent antithrombotic therapy is mandatory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H101619074#H101619074\">",
"     \"Carotid artery stenting and its complications\", section on 'Perioperative antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785750334\">",
"    <span class=\"h3\">",
"     Lytic therapy for patients with ischemic neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with blunt cerebrovascular injury who have a persistent neurologic deficit is similar to that of other stroke etiologies. Patients with ischemic neurologic symptoms within the hyperacute period may be eligible for thrombolytic therapy, provided there are no significant associated injuries to contraindicate its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link\">",
"     \"Management of acute severe traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21960?source=see_link&amp;anchor=H28007403#H28007403\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for the majority of patients with stroke due to blunt cerebrovascular injury, coexistent injuries will contraindicate lytic therapy, and for some, antithrombotic therapy as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259255\">",
"    <span class=\"h1\">",
"     FOLLOW-UP FOR HEALING OR PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no good long-term outcome data to guide the duration of antithrombotic therapy. Because a significant number of injuries evolve in a manner that alters therapy, we perform a follow-up study 7 to 10 days after the injury was identified (inpatient or outpatient), or for any change in neurologic status. If complete healing has been demonstrated by follow-up imaging, antithrombotic therapy can be discontinued.",
"   </p>",
"   <p>",
"    The dynamic nature of blunt cerebrovascular injury is illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 114 patients with blunt cerebrovascular injury, follow-up arteriography was performed within 10 days in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"       7",
"      </a>",
"      ]. Grade I and grade II injuries frequently changed, with 57 percent of grade I and 8 percent of grade II injuries healing completely, allowing cessation of treatment. Progression to pseudoaneurysm formation was seen in 8 percent of grade I and 43 percent of grade II lesions prompting interventional treatment. Higher grade injuries changed very little, with 93 percent of grade III and 82 percent of grade IV injuries remaining unchanged.",
"     </li>",
"     <li>",
"      A review of consecutive patients treated and followed over 10 years found 133 blunt cerebrovascular injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/19\">",
"       19",
"      </a>",
"      ]. Of the surviving patients, no patient experienced cerebral infarction after discharge. Angiographic follow-up was available for 50 patients representing 67 injuries at a mean of 6 months. Seventy-two percent of Grade I injuries were healed at follow up. Of the Grade II lesions, 40 percent worsened while 30 percent improved. The majority of Grade III lesions remained the same or enlarged, prompting treatment with endovascular stents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the lesion remains, the patients should be maintained on antithrombotic therapy but the optimal drug and duration of therapy have not been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. For those who do continue antithrombotic therapy, we obtain a study at three months following the injury to determine whether antithrombotic therapy can be discontinued, and if another treatment (eg, stenting) is needed. In the absence of documented healing of the vessel, it is reasonable to provide ongoing treatment, since delayed stroke can occur and has been reported as long as 14 years after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/45\">",
"     45",
"    </a>",
"    ]. We continue antiplatelet therapy (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , 80 mg daily) indefinitely for patients who do",
"    <strong>",
"     not",
"    </strong>",
"    demonstrate documented healing (ie, persistent flap, dissection) of the vessel on follow-up imaging (digital subtraction arteriography or computed tomographic [CT] angiography). However, for some patients, the risk of the imaging examination may be greater than simply continuing antithrombotic therapy.",
"   </p>",
"   <p>",
"    Studies identifying progression or healing of the vascular lesion have typically used conventional arteriography, but we prefer to use CT angiography (&ge;16 slice) because of its noninvasive nature. The advantages and disadvantages of the various imaging modalities for the evaluation of blunt cerebrovascular injury are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=see_link&amp;anchor=H3987108#H3987108\">",
"     \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\", section on 'Imaging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740622\">",
"    <span class=\"h1\">",
"     INJURY GRADE-SPECIFIC RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that determine the strategy for treatment and follow-up include symptoms, site of injury, severity or grade of injury, and the presence of associated injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740820\">",
"    <span class=\"h2\">",
"     Grade I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimal flap injuries have a low stroke risk and high rate of resolution with antithrombotic therapy. In one study, half of those that weren&rsquo;t even treated were healed at follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Initial treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or antiplatelet therapy is appropriate for grade I injuries, as there are no data demonstrating superiority of one over the other. We generally administer heparin in hospitalized patients who may be undergoing surgical procedures, because the effects can be quickly reversed. However, once the risk for bleeding is reduced, we transition to antiplatelet therapy given its low cost and simplicity of administration. We recommend antiplatelet therapy until the lesion is healed.",
"   </p>",
"   <p>",
"    Because these lesions do not have flow-limiting potential, additional treatment (surgical or endovascular) is",
"    <strong>",
"     not",
"    </strong>",
"    necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"     7",
"    </a>",
"    ]. We suggest follow-up imaging 7 to 10 days following the injury, or for any change in neurologic status. If the intimal flap has healed, antithrombotic therapy can be discontinued. Some patients with stable low-grade lesions may elect to continue antiplatelet therapy given the relatively low risk of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and forego numerous follow-up imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740848\">",
"    <span class=\"h2\">",
"     Grade II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial dissections often progress in spite of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. We recommend initiating antithrombotic therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for these patients, reserving antiplatelet therapy for those who have contraindications to heparin. We suggest follow-up imaging 7 to 10 days following the injury, or for any change in neurologic status. Long-term treatment with antiplatelet therapy appears to be adequate for stroke prevention for patients with stable lesions. Endovascular stenting may be indicated if carotid injury progresses to the point of near-occlusion. Stenting may be preferred since the distal extent of the injury often precludes adequate surgical control of the vessel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740862\">",
"    <span class=\"h2\">",
"     Grade III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial pseudoaneurysm injuries are less likely to heal compared with lower grade injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]. We recommend initiating antithrombotic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for these patients, reserving antiplatelet therapy for those who have contraindications to heparin. In one study, over half of pseudoaneurysms remained the same size or enlarged at a mean of six months. Intervention is generally warranted once a pseudoaneurysm reaches a size of 1.0 to 1.5 cm, or is symptomatic. Surgically-accessible carotid artery pseudoaneurysm can be treated with resection and repair (patch or interposition graft). Alternatively, arterial pseudoaneurysms (carotid or vertebral) can be treated using endovascular techniques (stent or coil embolization) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740876\">",
"    <span class=\"h2\">",
"     Grade IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries with complete arterial thrombosis are associated with high mortality and the neurologic outcome is proportional to the degree of neurologic impairment on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/3\">",
"     3",
"    </a>",
"    ]. When initially asymptomatic patients with arterial occlusion are treated with antithrombotic therapy; stroke rates are lower than with no treatment. We recommend initiating antithrombotic therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , reserving antiplatelet therapy for those with contraindications to heparin. In one study, 82 percent of grade IV injuries remaining unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"     7",
"    </a>",
"    ]. Over time, a small number of occlusions may recanalize. There are no data demonstrating any benefit for endovascular therapy or to guide long-term management. Since the follow-up examination is unlikely to change in a manner that will alter treatment, we suggest not obtaining a routine follow-up study. We generally suggest lifelong antiplatelet therapy for patients with occlusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785740974\">",
"    <span class=\"h2\">",
"     Grade V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transection injuries of the carotid artery are associated with high rates of stroke and high mortality. Hemorrhage from the neck as evidenced by an expanding hematoma (zone II) should be controlled by direct pressure until surgical control, if accessible, or endovascular control can be achieved. Hemorrhage from the mouth or ears is often indicative of a lesion that will require angioembolization for control.",
"   </p>",
"   <p>",
"    Surgically accessible carotid artery transections can be managed by exposing and controlling the vessel through a neck incision and performing a primary repair, if length permits, and if not, by using an interposition graft. Ligation of the vessel, at times, may be necessary.",
"   </p>",
"   <p>",
"    Inaccessible lesions often require embolization of the vessel to manage the hemorrhage. Angioembolization may be the best means of vascular control depending upon the site of the injury. Once the bleeding is under control the clinician should evaluate the risks versus benefits of antithrombotic therapy following stent placement or angioembolization. There are no data to guide this decision, other than that extrapolated from grade III or IV injuries. Follow-up imaging is recommended as per recommendations for grade III or IV injuries. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259262\">",
"    <span class=\"h1\">",
"     STROKE AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt cerebrovascular injury is historically associated with mortality rates ranging from 23 to 28 percent, with 48 to 58 percent of survivors having permanent severe neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/5\">",
"     5",
"    </a>",
"    ]. As more asymptomatic injuries have been identified, the absolute rate of stroke has decreased over time even though outcomes related to stroke remain poor. The use of antithrombotic therapy is associated with lower rates of stroke. (See",
"    <a class=\"local\" href=\"#H785733443\">",
"     'Antithrombotic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the carotid artery, stroke rates increase with increasing injury grade [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/6\">",
"     6",
"    </a>",
"    ]. Injuries with complete arterial thrombosis are associated with high mortality and poor neurologic outcome proportional to the degree of neurologic impairment on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/3\">",
"     3",
"    </a>",
"    ]. Internal carotid artery injuries result in mortality and stroke rates of 13 to 21 percent and 26 to 41 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/4,7,17\">",
"     4,7,17",
"    </a>",
"    ]. Mortality and stroke rates for common carotid injuries appear to be lower at 11 percent each [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H280052\">",
"     'Injury grading'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For vertebral injuries, the incidence of posterior circulation stroke is 14 to 24 percent, and the associated mortality is 4 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/17,47,48\">",
"     17,47,48",
"    </a>",
"    ]. Stroke incidence and neurologic outcomes are independent of blunt vertebral injury grade [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289479\">",
"    <span class=\"h1\">",
"     FUNCTIONAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no data looking specifically at functional outcomes of patients with blunt cerebrovascular injury compared with other etiologies of stroke, outcomes may be worse for blunt cerebrovascular injury given the high incidence of associated brain injury.",
"   </p>",
"   <p>",
"    A prospective study followed 133 consecutive patients with blunt carotid injuries over a 10-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinical follow-up was available in 55 of 81 patients who survived to discharge. The same or improved Glasgow outcome scale was found in 95 percent of the patients at a mean follow-up of 34 months. No patient experienced cerebral infarction or died following discharge from the hospital.",
"   </p>",
"   <p>",
"    For blunt vertebral injury, a review of the National Trauma Database found 574 patients with blunt vertebral injury among the 761,385 blunt trauma admissions (0.08 percent incidence) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8953/abstract/48\">",
"     48",
"    </a>",
"    ]. Overall mortality was 8 percent and stroke was diagnosed in 12 percent of patients who had no associated blunt carotid injury. Functional outcomes measures were available for 261 patients and about half the patients demonstrated functional independence upon discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259283\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blunt carotid and vertebral artery injury are collectively termed blunt cerebrovascular injury; they are rare but potentially morbid injuries. The overall incidence for these injuries is about one percent of blunt trauma admissions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=see_link&amp;anchor=H19563948#H19563948\">",
"       \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the carotid artery, stroke rates increase with increasing injury grade. Stroke incidence and neurologic outcome for vertebral injury are independent of injury grade. Injury grades for blunt cerebrovascular injury are as follows (see",
"      <a class=\"local\" href=\"#H280052\">",
"       'Injury grading'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H259262\">",
"       'Stroke and mortality'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Grade I: Intimal irregularity or dissection with &lt;25 percent luminal narrowing",
"     </li>",
"     <li>",
"      Grade II: Dissection or intramural hematomas with &ge;25 percent luminal narrowing, intraluminal clot, or a visible intimal flap",
"     </li>",
"     <li>",
"      Grade III: Pseudoaneurysm or hemodynamically insignificant arteriovenous fistula",
"     </li>",
"     <li>",
"      Grade IV: Complete occlusion",
"     </li>",
"     <li>",
"      Grade V: Transection with active extravasation, or hemodynamically significant arteriovenous fistula",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with blunt cerebrovascular injury who do not have a persistent neurologic deficit in the territory of the injured artery and who do not have contraindications, we recommend antithrombotic therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , antiplatelet agents) over no such therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Neurologic outcomes are improved in symptomatic patients, and fewer ischemic neurologic events (stroke) occur in asymptomatic patients who are treated with antithrombotic therapy. (See",
"      <a class=\"local\" href=\"#H259192\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients suspected of having blunt cerebrovascular injury, we suggest initiating unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      rather than antiplatelet therapy provided there are no contraindications to heparin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Antiplatelet therapy is an alternative depending upon the nature and extent of associated injuries. The duration of therapy is unknown; however, we continue antiplatelet therapy, typically",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (80 mg daily), indefinitely for patients who do",
"      <strong>",
"       not",
"      </strong>",
"      demonstrate documented healing of the vessel on follow-up imaging (digital subtraction arteriography or computed tomographic [CT] angiography). (See",
"      <a class=\"local\" href=\"#H785733542\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest exploration and repair of surgically-accessible Grade II through Grade V injuries to the cervical carotid artery, rather than endovascular repair or no repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, a majority of blunt cerebrovascular injuries involve the carotid artery at the base of the skull and these are not surgically-accessible. No studies are available directly comparing surgical versus endovascular management of surgically-accessible blunt cerebrovascular lesions. (See",
"      <a class=\"local\" href=\"#H785732816\">",
"       'Surgery for accessible lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular techniques can be used to manage surgically inaccessible blunt cerebrovascular injuries with a flow-limiting stenosis (Grade II), pseudoaneurysm formation (Grade III), or transection (Grade V). (See",
"      <a class=\"local\" href=\"#H785732723\">",
"       'Endovascular therapy for inaccessible lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain follow-up 7 to 10 days following identification of the cerebrovascular injury using CT angiography. Routine follow-up imaging is",
"      <strong>",
"       not",
"      </strong>",
"      needed for patients with complete occlusion (Grade IV). For most patients who remain on antithrombotic therapy, we routinely schedule CT angiography at three months, to determine if long-term antithrombotic therapy is needed. Progression of the injury under certain circumstances may indicate the need for intervention. Further imaging in patients who have undergone definitive repair (surgical or endovascular) is guided by the nature of the intervention. (See",
"      <a class=\"local\" href=\"#H259255\">",
"       'Follow-up for healing or progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H785740622\">",
"       'Injury grade-specific recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/1\">",
"      Davis JW, Holbrook TL, Hoyt DB, et al. Blunt carotid artery dissection: incidence, associated injuries, screening, and treatment. J Trauma 1990; 30:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/2\">",
"      Martin RF, Eldrup-Jorgensen J, Clark DE, Bredenberg CE. Blunt trauma to the carotid arteries. J Vasc Surg 1991; 14:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/3\">",
"      Cogbill TH, Moore EE, Meissner M, et al. The spectrum of blunt injury to the carotid artery: a multicenter perspective. J Trauma 1994; 37:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/4\">",
"      Ramadan F, Rutledge R, Oller D, et al. Carotid artery trauma: a review of contemporary trauma center experiences. J Vasc Surg 1995; 21:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/5\">",
"      Biffl WL, Moore EE, Ryu RK, et al. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. Ann Surg 1998; 228:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/6\">",
"      Biffl WL, Moore EE, Offner PJ, et al. Blunt carotid arterial injuries: implications of a new grading scale. J Trauma 1999; 47:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/7\">",
"      Biffl WL, Ray CE Jr, Moore EE, et al. Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography. Ann Surg 2002; 235:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/8\">",
"      Tisherman SA, Bokhari F, Collier B, et al. Clinical practice guideline: penetrating zone II neck trauma. J Trauma 2008; 64:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/9\">",
"      Biffl WL, Cothren CC, Moore EE, et al. Western Trauma Association critical decisions in trauma: screening for and treatment of blunt cerebrovascular injuries. J Trauma 2009; 67:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/10\">",
"      Bromberg WJ, Collier BC, Diebel LN, et al. Blunt cerebrovascular injury practice management guidelines: the Eastern Association for the Surgery of Trauma. J Trauma 2010; 68:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/11\">",
"      Parikh AA, Luchette FA, Valente JF, et al. Blunt carotid artery injuries. J Am Coll Surg 1997; 185:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/12\">",
"      Fabian TC, George SM Jr, Croce MA, et al. Carotid artery trauma: management based on mechanism of injury. J Trauma 1990; 30:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/13\">",
"      Cothren CC, Biffl WL, Moore EE, et al. Treatment for blunt cerebrovascular injuries: equivalence of anticoagulation and antiplatelet agents. Arch Surg 2009; 144:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/14\">",
"      Cothren CC, Moore EE, Ray CE Jr, et al. Screening for blunt cerebrovascular injuries is cost-effective. Am J Surg 2005; 190:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/15\">",
"      Miller PR, Fabian TC, Croce MA, et al. Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes. Ann Surg 2002; 236:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/16\">",
"      Schneidereit NP, Simons R, Nicolaou S, et al. Utility of screening for blunt vascular neck injuries with computed tomographic angiography. J Trauma 2006; 60:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/17\">",
"      Miller PR, Fabian TC, Bee TK, et al. Blunt cerebrovascular injuries: diagnosis and treatment. J Trauma 2001; 51:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/18\">",
"      Cothren CC, Moore EE, Biffl WL, et al. Anticoagulation is the gold standard therapy for blunt carotid injuries to reduce stroke rate. Arch Surg 2004; 139:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/19\">",
"      Edwards NM, Fabian TC, Claridge JA, et al. Antithrombotic therapy and endovascular stents are effective treatment for blunt carotid injuries: results from longterm followup. J Am Coll Surg 2007; 204:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/20\">",
"      Prall JA, Brega KE, Coldwell DM, Breeze RE. Incidence of unsuspected blunt carotid artery injury. Neurosurgery 1998; 42:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/21\">",
"      Fabian TC, Patton JH Jr, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. Ann Surg 1996; 223:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/22\">",
"      Colella JJ, Diamond DL. Blunt carotid injury: reassessing the role of anticoagulation. Am Surg 1996; 62:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/23\">",
"      Eachempati SR, Vaslef SN, Sebastian MW, Reed RL 2nd. Blunt vascular injuries of the head and neck: is heparinization necessary? J Trauma 1998; 45:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/24\">",
"      Wahl WL, Brandt MM, Thompson BG, et al. Antiplatelet therapy: an alternative to heparin for blunt carotid injury. J Trauma 2002; 52:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/25\">",
"      Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother 2008; 42:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/26\">",
"      Stein DM, Boswell S, Sliker CW, et al. Blunt cerebrovascular injuries: does treatment always matter? J Trauma 2009; 66:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/27\">",
"      Perry MO, Snyder WH, Thal ER. Carotid artery injuries caused by blunt trauma. Ann Surg 1980; 192:74.",
"     </a>",
"    </li>",
"    <li>",
"     Troop BR, Carr SC, Hurley JJ, Pennell RJ. Blunt carotid injuries. Contemp Surg. 1996;48:280.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/29\">",
"      Krajewski LP, Hertzer NR. Blunt carotid artery trauma: report of two cases and review of the literature. Ann Surg 1980; 191:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/30\">",
"      Nanda A, Vannemreddy PS, Willis BK, et al. Management of carotid artery injuries: Louisiana State University Shreveport experience. Surg Neurol 2003; 59:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/31\">",
"      Richardson JD, Simpson C, Miller FB. Management of carotid artery trauma. Surgery 1988; 104:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/32\">",
"      Unger SW, Tucker WS Jr, Mrdeza MA, et al. Carotid arterial trauma. Surgery 1980; 87:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/33\">",
"      Karlin RM, Marks C. Extracranial carotid artery injury. Current surgical management. Am J Surg 1983; 146:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/34\">",
"      Ledgerwood AM, Mullins RJ, Lucas CE. Primary repair vs ligation for carotid artery injuries. Arch Surg 1980; 115:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/35\">",
"      Vishteh AG, Marciano FF, David CA, et al. Long-term graft patency rates and clinical outcomes after revascularization for symptomatic traumatic internal carotid artery dissection. Neurosurgery 1998; 43:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/36\">",
"      Halbach VV, Higashida RT, Dowd CF, et al. Endovascular treatment of vertebral artery dissections and pseudoaneurysms. J Neurosurg 1993; 79:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/37\">",
"      Yee LF, Olcott EW, Knudson MM, Lim RC Jr. Extraluminal, transluminal, and observational treatment for vertebral artery injuries. J Trauma 1995; 39:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/38\">",
"      Duke BJ, Ryu RK, Coldwell DM, Brega KE. Treatment of blunt injury to the carotid artery by using endovascular stents: an early experience. J Neurosurg 1997; 87:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/39\">",
"      Li W, D'Ayala M, Hirshberg A, et al. Comparison of conservative and operative treatment for blunt carotid injuries: analysis of the National Trauma Data Bank. J Vasc Surg 2010; 51:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/40\">",
"      Moulakakis KG, Mylonas S, Avgerinos E, et al. An update of the role of endovascular repair in blunt carotid artery trauma. Eur J Vasc Endovasc Surg 2010; 40:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/41\">",
"      Berne JD, Reuland KR, Villarreal DH, et al. Internal carotid artery stenting for blunt carotid artery injuries with an associated pseudoaneurysm. J Trauma 2008; 64:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/42\">",
"      Cohen JE, Gomori JM, Itshayek E, et al. Single-center experience on endovascular reconstruction of traumatic internal carotid artery dissections. J Trauma Acute Care Surg 2012; 72:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/43\">",
"      Stager V, Gandhi R, Stroman D, et al. Traumatic internal carotid artery injury treated with overlapping bare metal stents under intravascular ultrasound guidance. J Vasc Surg 2011; 53:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/44\">",
"      Cothren CC, Moore EE, Ray CE Jr, et al. Carotid artery stents for blunt cerebrovascular injury: risks exceed benefits. Arch Surg 2005; 140:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/45\">",
"      Mokri B, Piepgras DG, Houser OW. Traumatic dissections of the extracranial internal carotid artery. J Neurosurg 1988; 68:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/46\">",
"      Cox MW, Whittaker DR, Martinez C, et al. Traumatic pseudoaneurysms of the head and neck: early endovascular intervention. J Vasc Surg 2007; 46:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/47\">",
"      Biffl WL, Moore EE, Elliott JP, et al. The devastating potential of blunt vertebral arterial injuries. Ann Surg 2000; 231:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8953/abstract/48\">",
"      Spaniolas K, Velmahos GC, Alam HB, et al. Does improved detection of blunt vertebral artery injuries lead to improved outcomes? Analysis of the National Trauma Data Bank. World J Surg 2008; 32:2190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16136 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8953=[""].join("\n");
var outline_f8_47_8953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H259283\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H273294\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H280052\">",
"      INJURY GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259192\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785733443\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H785733542\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H785733569\">",
"      - Monitoring and complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H785740391\">",
"      - Contraindications to antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785734511\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H785732816\">",
"      - Surgery for accessible lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H785732723\">",
"      - Endovascular therapy for inaccessible lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H785750334\">",
"      - Lytic therapy for patients with ischemic neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259255\">",
"      FOLLOW-UP FOR HEALING OR PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H785740622\">",
"      INJURY GRADE-SPECIFIC RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785740820\">",
"      Grade I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785740848\">",
"      Grade II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785740862\">",
"      Grade III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785740876\">",
"      Grade IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H785740974\">",
"      Grade V",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259262\">",
"      STROKE AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289479\">",
"      FUNCTIONAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H259283\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16136|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/42/1698\" title=\"algorithm 1\">",
"      Blunt cerebrovascular injury algorithm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=related_link\">",
"      Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=related_link\">",
"      Carotid artery stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=related_link\">",
"      Penetrating neck injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21960?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8954="Management of primary hyperparathyroidism";
var content_f8_47_8954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of primary hyperparathyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Shonni J Silverberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/47/8954/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/47/8954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism (PHPT) is often recognized as a result of biochemical screening or as part of an evaluation for decreased bone mass. Most of the patients have serum calcium concentrations within 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.25 to 0.375",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    above the upper limit of normal. Among such patients, the majority are women over age 50 years, and many have symptoms that are difficult to quantify. Because of the largely subjective nature of symptoms, the distinction between asymptomatic and symptomatic PHPT is not always clear-cut. Patients may deny symptoms, whereas a family member may say the patient has been mildly symptomatic in some way [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with symptomatic primary hyperparathyroidism should have parathyroid surgery, the widespread identification of asymptomatic individuals raises the question of need for and timing of surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Although most asymptomatic patients do not have progression of disease, as defined by worsening hypercalcemia, hypercalciuria, bone disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrolithiasis, some individuals do progress and would benefit from surgical cure. Thus, the primary goal is to identify the asymptomatic individuals at risk for disease progression, as well as those who have features of the disease that may improve following parathyroidectomy. These two groups of individuals would likely benefit from surgical intervention.",
"   </p>",
"   <p>",
"    This topic reviews how to identify these individuals and the risks and benefits of medical versus surgical management in this population. Diagnostic localization of abnormal parathyroid glands and the methods of surgical removal are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision regarding medical versus surgical treatment does not apply to patients who have familial hypocalciuric hypercalcemia. Patients with this disorder have mild hypercalcemia, few if any symptoms, no evidence of end organ damage from their disease, and no benefit from parathyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGERY VERSUS MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic primary hyperparathyroidism should have parathyroid surgery. However, many patients with hyperparathyroidism are asymptomatic or have nonclassical manifestations of their disease. Parathyroidectomy is an effective therapy that cures the disease, decreases the risk of kidney stones, improves bone mineral density, and may decrease fracture risk and modestly improve some quality of life measurements. In addition, proponents of surgery for asymptomatic individuals argue that many untreated patients are lost to follow-up after 5 to 10 years and that the cost of follow-up visits and tests may ultimately exceed the costs of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Thus, some argue that parathyroidectomy is an attractive strategy for nearly all patients, particularly with recent significant progress in techniques for minimally invasive surgical extirpation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proponents who favor nonoperative management for asymptomatic individuals cite the lack of disease progression in the majority of patients and the ability to treat, if necessary, with alternative therapies as reasons to avoid an invasive procedure. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Alternatives to surgery'",
"    </a>",
"    below.) Thus, the debate regarding treatment of asymptomatic PHPT revolves around the effect of intervention on outcomes, such as symptoms, bone disease, and biochemical abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Neuropsychiatric",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although only a minority of patients with mild primary hyperparathyroidism (PHPT) have the classic symptoms of the disease (nephrolithiasis or overt bone disease, osteitis fibrosa cystica), they may have nonspecific symptoms. These symptoms include fatigue, a sense of weakness, mild depression, and memory impairment; their reversal after surgery in some patients suggests that they were caused by the hypercalcemia or the hypersecretion of parathyroid hormone (PTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/9-18\">",
"     9-18",
"    </a>",
"    ]. However, most of the studies reporting symptomatic improvement were observational and were limited by selection bias, inclusion of subjects with symptomatic hyperparathyroidism, lack of an adequate control group, or of validated instruments to describe neuropsychiatric symptoms.",
"   </p>",
"   <p>",
"    Long-term randomized controlled trials are necessary to determine the benefits of surgery in reducing symptoms. However, randomized trials also have limitations, including difficulty recruiting asymptomatic patients who will accept randomization to surgery. Subjects who choose to participate may well differ from those who decline enrollment, decreasing the generalizability of the results to all patients with asymptomatic PHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, withdrawal rates are high due to a variety of reasons, including discontent with initial treatment assignment. Despite these limitations, the results of randomized trials assessing the benefit of surgery versus observation on neuropsychiatric symptoms in individuals with asymptomatic PHPT provide important information [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 53 of 283 potentially eligible patients (calcium between 10.1 and 11.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.52 to 2.87",
"      <span class=\"nowrap\">",
"       mmol/liter])",
"      </span>",
"      agreed to be randomly assigned to surgery or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. At baseline, mean Short Form-36 (SF-36) Health Survey scores were similar to published normals. Those who underwent successful surgery (traditional neck exploration) had little change in psychosocial functioning two years later, but there was a significant decline over time in the observation group. After a median follow-up of 42 months, there was a significant benefit of surgery compared with no surgery in two of nine domains of the SF-36 survey (social functioning and emotional problems) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, 191 patients (mean calcium 10.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      were randomly assigned to medical observation or surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/21\">",
"       21",
"      </a>",
"      ]. At baseline, all patients had lower scores in the psychological and mental component domains of the SF-36 and Comprehensive Psychopathological Rating Scale, respectively, compared with an age- and gender-matched database. In an interim analysis after two years of follow-up (99 subjects), there were no clinically significant improvements in either group. There were small differences in the physical and emotional domains over two years, favoring surgery.",
"     </li>",
"     <li>",
"      In a one-year trial of 50 patients (mean calcium 10.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.55",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      randomly assigned to observation or parathyroidectomy, there was modest improvement in some SF-36 quality of life domains (bodily pain, general health, vitality, and mental health) in patients assigned to surgery compared with observation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, current randomized trial data suggest minimal to modest differences in some domains of the SF-36, favoring surgical intervention. The fact that improvements were noted in differing domains of the SF-36 in the different trials suggests that individual patients cannot have specific expectations regarding surgical outcome for neuropsychiatric symptoms. In addition, the differences were very small and of uncertain clinical significance. Continued follow-up and additional studies are warranted to determine whether these benefits outweigh surgical risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important renal manifestations of PHPT are nephrolithiasis, hypercalciuria, nephrocalcinosis, chronic renal insufficiency, and several abnormalities in renal tubular function, in particular, decreased concentrating ability. Nephrolithiasis occurs in approximately 15 to 20 percent of patients with primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Nephrolithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies report a marked reduction in formation of kidney stones after successful surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Furthermore, over a 10-year follow-up period, all patients with a history of nephrolithiasis who did not choose to have parathyroidectomy had progression of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, a history of nephrolithiasis is regarded as a clear indication for surgery.",
"   </p>",
"   <p>",
"    Most stones in patients with hyperparathyroidism are composed of calcium oxalate. A contributing factor for stone formation in hyperparathyroidism is hypercalciuria. However, urinary calcium excretion per gram creatinine does not necessarily differentiate patients with or without stones, nor does it predict the development of kidney stones in an individual patient. Thus, in the absence of kidney stones, hypercalciuria is not considered an indication for surgery in patients with asymptomatic primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Nephrolithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies in Europe have reported increased cardiovascular morbidity and mortality in patients with otherwise asymptomatic hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    .) Survival benefit has also been demonstrated post-parathyroidectomy in several large cohort studies from Sweden and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]; however, the survival benefit was not observed until 15 years post-parathyroidectomy in the largest study published to date [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A population-based study from the United States did not find an increase in mortality in patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/30\">",
"     30",
"    </a>",
"    ]. In this study of 435 patients, cardiovascular mortality was reduced in patients with PHPT compared with age and gender matched residents of the same community (relative risk 0.6, 95% CI 0.4-0.8). One explanation for the incongruent mortality data is that more patients in the US studies had mild disease with lower serum calcium levels (mean calcium 10.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and fewer symptoms than patients in the European studies, where average calcium levels were significantly higher.",
"   </p>",
"   <p>",
"    Other cardiovascular features of classical PHPT include hypertension, arrhythmia, ventricular hypertrophy, and vascular and valvular calcification. The extent to which such findings persist in those with mild asymptomatic disease is unclear. In one observational study, successful surgery was associated with regression of left ventricular hypertrophy in patients who did not have hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/31\">",
"     31",
"    </a>",
"    ]. Although hypertension is frequently seen in association with PHPT even among those with mild disease, the majority of observational studies indicate that hypertension is not reversible with surgical cure and should not be used as an indication for parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few randomized trials with cardiovascular endpoints. In a two-year analysis of a randomized trial of parathyroidectomy versus observation in 116 patients with asymptomatic primary hyperparathyroidism, mean arterial and diastolic blood pressure declined in both groups with no significant difference between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/34\">",
"     34",
"    </a>",
"    ]. There were also no differences between the two groups in lipids, adiponectin, leptin, c-reactive protein, or biochemical markers of endothelial function (eg, vascular cell adhesion molecule 1, Von Willebrand factor).",
"   </p>",
"   <p>",
"    Current research is focusing on more subtle abnormalities of the cardiovascular system. The nature of such involvement, and the extent to which any abnormalities improve post-operatively, need to be elucidated before recommending surgery based upon such considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with asymptomatic hyperparathyroidism may have decreased bone mineral density (BMD), in particular at more cortical sites (forearm and hip) as compared with more trabecular sites (spine) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the reduction is usually small [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/36\">",
"     36",
"    </a>",
"    ]. As an example, in one study of 24 patients followed for three years, only 12 percent had bone density at the hip and spine of more than 1.5 SD lower than age- and sex-matched normal subjects, although 52 percent had a low score for the distal radius [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have demonstrated increased BMD following parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/21-23,34\">",
"     21-23,34",
"    </a>",
"    ]. In one trial, lumbar spine BMD increased in the surgical group compared with the medical group two years after surgery; spine BMD remained unchanged in the medical group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/21\">",
"     21",
"    </a>",
"    ]. A similar but nonsignificant trend was noted at the femoral neck. In another randomized trial, BMD after two years was slightly better at the femoral neck and total hip (but not spine) in the surgical compared to the non-surgical group (group differences of 0.8 and 1.0",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    at the femoral neck and hip, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant improvement in bone mineral density post-parathyroidectomy has been noted in observational studies also [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/25,38-41\">",
"     25,38-41",
"    </a>",
"    ]. In one prospective study of a cohort of 121 patients with hyperparathyroidism followed for up to 10 years, there were substantial increments in bone mineral density of 12 to 15 percent in those who underwent parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/25\">",
"     25",
"    </a>",
"    ]. Most of the increments occurred within the first year at the lumbar spine and within the first two years at the hip.",
"   </p>",
"   <p>",
"    In most [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/25,39,40,42-44\">",
"     25,39,40,42-44",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] studies, the initial years of observation without surgical intervention were not associated with progressive bone loss. In a 15-year follow-up of the prospective cohort study described above, lumbar spine BMD remained stable in the six patients observed without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/47\">",
"     47",
"    </a>",
"    ]. In contrast, BMD started to fall at cortical sites, ultimately decreasing at the femoral neck and distal radius by 10 and 35 percent, respectively. Although the sample size after 10 years was limited, these data raise the question as to whether non-surgical management of primary hyperparathyroidism should be limited to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/26,48\">",
"     26,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although one small study suggested that asymptomatic PHPT was not a risk factor for vertebral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/49\">",
"     49",
"    </a>",
"    ], observations from large case-control and cohort studies suggest that there may be increased fracture risk at vertebral and other skeletal sites [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/29,50-52\">",
"     29,50-52",
"    </a>",
"    ]. Observational data suggest that fracture risk is decreased after parathyroidectomy, but there are no randomized data addressing this question [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/29,50\">",
"     29,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Biochemical abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized studies, there is little evidence that hypercalcemia worsens or renal function deteriorates in the majority of asymptomatic patients followed for two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. However, in one study, 8 percent of asymptomatic patients randomly assigned to observation developed worsening hypercalcemia requiring surgery (over a two-year interval) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies of longer duration (up to 15 years) report similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/6,32,38,53,54\">",
"     6,32,38,53,54",
"    </a>",
"    ]. Biochemical abnormalities remain stable in the majority, but patients occasionally become spontaneously normocalcemic during follow up, and a small proportion develop worsening biochemical parameters requiring surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/25,32,53,54\">",
"     25,32,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 52 asymptomatic patients followed for up to 10 years, there was no change in mean serum calcium and PTH concentrations and urinary calcium excretion (or bone mineral density), but one or more of these measures increased substantially in 14 (27 percent of) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/25\">",
"     25",
"    </a>",
"    ], and after 15 years of observation, 37 percent of patients had evidence of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/47\">",
"     47",
"    </a>",
"    ]. These patients were younger at baseline than those without disease progression (52 versus 60 years of age), and several became menopausal during follow-up. Thus, younger age (&lt;50 years) at diagnosis has been identified as a risk factor for disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of parathyroid surgery is biochemical cure of PHPT. Traditionally the standard surgical approach for most patients with PHPT is bilateral neck exploration, usually under general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/4\">",
"     4",
"    </a>",
"    ]. Bilateral exploration relies on visual and weight-based estimations of gland size to distinguish single adenoma from multiglandular disease. However, with increased experience, improved imaging modalities, and the use of adjuncts such as intraoperative PTH monitoring (IOPTH), minimally invasive parathyroidectomy (MIP) is emerging as the procedure of choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466865#H10466865\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Focused parathyroid exploration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cure rates of bilateral neck exploration and MIP are similar (95 to 98 versus 96 to 100 percent) when MIP is performed in the appropriate patient population, and complication rates with both are low with an experienced surgeon. Increasing use of MIP is expected to further decrease surgical risk and may therefore tip the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio towards surgery in patients with asymptomatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466865#H10466865\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Focused parathyroid exploration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23978864\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism is uncommon during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. However, moderate to severe hypercalcemia during pregnancy may carry significant maternal and fetal risks. In case reports and case series, maternal presentation included hyperemesis, nephrolithiasis, recurrent urinary tract infection, and pancreatitis. Neonatal complications included hypocalcemia and tetany, secondary to fetal PTH suppression, preterm delivery, low birth weight, and fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/57,60\">",
"     57,60",
"    </a>",
"    ]. These outcomes are very uncommon in pregnancies of patients with mild hypercalcemia.",
"   </p>",
"   <p>",
"    As in nonpregnant patients, treatment is based upon severity and symptoms, but consideration of gestational age is also important. When interpreting the severity of serum calcium elevations in pregnant women, it is important to remember that total serum calcium declines across gestation, likely due to plasma volume expansion. The upper limit of normal for total serum calcium is 9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in pregnancy. The active, ionized calcium level does not change significantly during a normal pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=see_link&amp;anchor=H3#H3\">",
"     \"Calcium physiology in pregnancy\", section on 'Calcium concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery during the second trimester is the preferred treatment for symptomatic patients; however, observation may be appropriate in some circumstances (for some patients with asymptomatic very mild hypercalcemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/61\">",
"     61",
"    </a>",
"    ]. In one small series, surgery was successfully performed in 15 of 16 patients during the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/62\">",
"     62",
"    </a>",
"    ]. In pregnant patients undergoing minimally invasive parathyroid surgery, localization is done with ultrasound, rather than sestamibi. If a woman with diagnosed primary hyperparathyroidism plans a pregnancy, parathyroidectomy should be done prior to conception. If a patient is followed through her pregnancy with very mild hypercalcemia, it is important to alert neonatologists to the possibility of hypocalcemia in the newborn (due to possible suppression of the fetal parathyroid gland).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic primary hyperparathyroidism (PHPT) should have parathyroid surgery. The widespread identification of asymptomatic individuals raises the question of if and when these individuals should undergo surgery.",
"   </p>",
"   <p>",
"    Although parathyroidectomy improves bone density and may have modest effects on some quality of life symptoms, long-term observational data and short-term randomized trial data clearly demonstrate that a large subgroup of patients with asymptomatic PHPT can be followed safely without surgery because they do not have disease progression, as evidenced by stable biochemical abnormalities and BMD for up to a decade of observation. However, disease may progress (worsening hypercalcemia, hypercalciuria, newly diagnosed nephrolithiasis) in as many as one-third of patients over the first years of observation, and these patients would benefit from surgical intervention. In addition, BMD declines in most patients observed for longer than 8 to 10 years. Although these observational data are based upon a small number of patients, they do suggest that long-term (&gt;8 to 10 years) observation in asymptomatic patients is not optimal for skeletal outcomes. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Bone disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ability to identify criteria that are predictive of disease progression would improve management strategies, but these factors (other than age &lt;50 years at presentation) are as yet unknown. Therefore, asymptomatic patients who do not undergo surgery require long-term monitoring for worsening hypercalcemia, renal impairment, and bone loss. The development of any of these findings indicates disease progression and the need for surgical intervention. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2002 NIH Workshop on Asymptomatic Primary Hyperparathyroidism developed criteria for surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/63\">",
"     63",
"    </a>",
"    ]. The criteria were revised at the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/64\">",
"     64",
"    </a>",
"    ]. These criteria were chosen on the basis of clinical experience and observational and clinical trial data as to which patients are more likely to have end-organ effects of primary hyperparathyroidism (nephrolithiasis, skeletal involvement), disease progression if surgery is deferred, and the most benefit from surgery. The panel emphasized the need for parathyroidectomy to be performed by surgeons who are highly experienced and skilled in the operation. The Third International Workshop guidelines concluded that surgery is indicated in asymptomatic patients who meet any one of the following conditions (",
"    <a class=\"graphic graphic_table graphicRef63054 \" href=\"UTD.htm?17/13/17628\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum calcium concentration of 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.25",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or more above the upper limit of normal",
"     </li>",
"     <li>",
"      Creatinine clearance that is reduced to &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      Bone density at the hip, lumbar spine, or distal radius that is more than 2.5 standard deviations below peak bone mass (T score &lt;-2.5)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      previous fragility fracture",
"     </li>",
"     <li>",
"      Age less than 50 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Operative intervention can be delayed in patients over 50 years of age who are asymptomatic or minimally symptomatic and who have serum calcium concentrations &lt;1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    above the upper limit of normal, and in patients who are medically unfit for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If surgery is not recommended or the patient refuses, then it is appropriate to recommend supportive-preventive measures with adequate monitoring. Treatment with antiresorptive agents may be indicated in patients with osteopenia or osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of measures should be recommended to patients who do not undergo surgery, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid factors that can aggravate hypercalcemia, including thiazide diuretic and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      carbonate therapy, volume depletion, prolonged bed rest or inactivity, and a high calcium diet (&gt;1000",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"       \"Diuretics and calcium balance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Encourage physical activity to minimize bone resorption.",
"     </li>",
"     <li>",
"      Encourage adequate hydration (at least eight glasses of water per day) to minimize the risk of nephrolithiasis.",
"     </li>",
"     <li>",
"      Maintain a moderate calcium intake (1000",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link&amp;anchor=H18#H18\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Primary hyperparathyroidism'",
"      </a>",
"      .) A low calcium diet may lead to further increases in PTH secretion and could aggravate bone disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/65\">",
"       65",
"      </a>",
"      ]. However, in patients with high serum calcitriol concentrations, the recommended calcium intake has been shown to exacerbate hypercalcemia or hypercalciuria. Thus, moderate calcium restriction (eg, &lt;800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is probably warranted when the serum calcitriol concentration is high [",
"      <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maintain moderate vitamin D intake (400 to 600 International Units daily). Vitamin D deficiency stimulates PTH secretion and bone resorption and, therefore, is deleterious in patients with primary hyperparathyroidism. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of concomitant vitamin D deficiency'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic monitoring should be performed for disease progression and development of indications for surgery (",
"    <a class=\"graphic graphic_table graphicRef63054 \" href=\"UTD.htm?17/13/17628\">",
"     table 1",
"    </a>",
"    ). Measurements of serum calcium and creatinine annually and bone density (hip, spine, and forearm) every one to two years is sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/64\">",
"     64",
"    </a>",
"    ]. While confirmation of the absence of silent nephrolithiasis at the time of the original evaluation is sometimes recommended, monitoring with serial ultrasounds is not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Renal imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications have been used in patients with primary hyperparathyroidism, although they are not primarily indicated for this purpose. They include bisphosphonates and estrogen plus progestin, which inhibit bone resorption and can increase bone density and possibly lower serum calcium concentrations in patients with hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/67\">",
"     67",
"    </a>",
"    ]. Other medications, such as calcimimetics or vitamin D analogues, suppress parathyroid hormone release or counteract the effects of hyperparathyroidism at the level of the PTH receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are potent inhibitors of bone resorption and may be useful in the long-term control of osteopenia in patients with untreated primary hyperparathyroidism (PHPT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link\">",
"     \"Pharmacology of bisphosphonates\"",
"    </a>",
"    .) For patients with PHPT and osteopenia or osteoporosis who do not meet surgical criteria or who prefer to avoid surgery, we suggest bisphosphonates. However, documentation that the bone density benefit is sustained and accompanied by fracture reduction is needed. In addition, the increases in BMD with bisphosphonate therapy do not match those seen after parathyroidectomy. Thus, surgery remains the treatment of choice for osteoporotic patients with primary hyperparathyroidism.",
"   </p>",
"   <p>",
"    In four studies in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    was given to patients with mild PHPT for one to two years, bone density increased at the hip and lumbar spine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/68-71\">",
"     68-71",
"    </a>",
"    ] (but not radius [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/71\">",
"     71",
"    </a>",
"    ]) as compared with untreated or placebo-treated patients. As an example, in two of the studies, lumbar spine BMD increased by 7 to 8 percent and femoral neck BMD by 4 to 5 percent in the treated patients when compared with baseline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the untreated group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/68,71\">",
"     68,71",
"    </a>",
"    ]. In two other studies, there were small transient increases in serum PTH concentrations and small transient decreases in serum calcium concentrations and urinary calcium excretion in the first months of alendronate treatment, but the values then returned to baseline for the duration of the two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The influence of prior bisphosphonate use on post-surgical bone density improvement, should surgery become necessary, is unknown. In studies of recombinant PTH for the treatment of osteoporosis, the prior administration of some bisphosphonate blunts the improvement in BMD attained with PTH alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link&amp;anchor=H17#H17\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Combination therapy'",
"    </a>",
"    .) Thus, bone remodeling is necessary for the intermittent administration of recombinant parathyroid hormone to exert its beneficial effects on bone density and fracture prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Calcimimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcimimetic agents activate the calcium-sensing receptor in the parathyroid gland, thereby inhibiting PTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/72\">",
"     72",
"    </a>",
"    ]. Functions of the calcium-sensing receptor are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only one calcimimetic drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , is available for the treatment of secondary hyperparathyroidism associated with renal failure, for hypercalcemia in parathyroid cancer, and for the treatment of severe hypercalcemia in patients with primary hyperparathyroidism unable to undergo parathyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"     \"Parathyroid carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    reduces serum calcium in the majority of patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. As an example, in a one-year trial of 78 patients with PHPT randomly assigned to cinacalcet or placebo (12-week dose-titration, 12-week maintenance, and 28-week follow-up phases), cinacalcet therapy normalized serum calcium in 73 percent of subjects compared with only 5 percent in the placebo group. Serum PTH concentrations decreased by 7.5 percent with cinacalcet, but increased in the placebo group. Bone mineral density was unchanged in both groups, and there was no significant difference in the 24-hour urinary calcium-creatinine ratio between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/74\">",
"     74",
"    </a>",
"    ]. In an open-label extension study, 45 patients (21 and 24 of those originally assigned to cinacalcet and placebo, respectively) were treated with cinacalcet (30 to 50 mg twice daily) for up to 4.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/76\">",
"     76",
"    </a>",
"    ]. Cinacalcet maintained normocalcemia and reduced PTH in the majority of patients (74 to 92 percent), with no changes in bone mineral density. In a pooled analysis of data from three trials, cinacalcet was equally effective in reducing serum calcium in patients across a broad spectrum of disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/77\">",
"     77",
"    </a>",
"    ]. Side effects most commonly reported included nausea, arthralgia, diarrhea, myalgia, and paresthesia, occurring in 36, 30, 22, 22, and 22 percent of patients, respectively.",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    is not the medical equivalent of parathyroidectomy, because it is not permanent and there is no improvement in BMD. Furthermore, PTH concentrations do not normalize, and data are lacking on any salutary effect of cinacalcet on nephrolithiasis. However, cinacalcet can be used to normalize serum calcium in symptomatic patients who are unable to undergo parathyroidectomy or to determine the potential benefits of lowering serum calcium in complex patients with significant comorbidities who are considering parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/67\">",
"     67",
"    </a>",
"    ]. In such patients, we typically give cinacalcet at a dose of 30 mg twice daily. Serum calcium should be measured within one week after initiation or any dose adjustment.",
"   </p>",
"   <p>",
"    Currently, there are no data on the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    on subtle neuropsychiatric or cognitive abnormalities in the disease or in patient-reported quality of life outcomes. Thus, cinacalcet is not indicated in patients with mild asymptomatic primary hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14645494\">",
"    <span class=\"h3\">",
"     Estrogen-progestin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen-progestin therapy is beneficial in postmenopausal women with primary hyperparathyroidism because of its ability to reduce bone resorption. In two trials, serum calcium concentrations decreased by 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.12 to 0.24",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and bone density increased slightly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a third, larger trial, 42 women with mild hyperparathyroidism were randomly assigned to treatment with placebo or conjugated estrogens (0.625",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/45\">",
"     45",
"    </a>",
"    ]. Total body and forearm bone density fell by 2.3 and 3.5 percent, respectively, in the placebo group and increased by 1.3 and 3.4 percent, respectively, in the estrogen-progestin group. Lumbar spine and femoral neck bone density also increased in the latter group. There was no change in serum calcium or PTH concentrations in either group. Twenty-three of the 42 women then participated in an extension study for an additional two years (total of four years) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/80\">",
"     80",
"    </a>",
"    ]. The beneficial effect of hormone therapy on bone density persisted at year four, with between-group differences in hip, lumbar spine, and forearm bone density that ranged from 7 to 8.2 percent.",
"   </p>",
"   <p>",
"    In addition, a small prospective trial suggested that improvements in bone mineral density after parathyroidectomy are most substantial in a subset of women given concomitant postmenopausal hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/81\">",
"     81",
"    </a>",
"    ]. However, there are significant risks associated with estrogen-progestin therapy, including increased risks of breast cancer, stroke, and coronary heart disease. Therefore, estrogen or estrogen-progestin therapy should not be a first-line therapy for women with primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14645600\">",
"    <span class=\"h3\">",
"     Raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    , a selective estrogen receptor modulator is available in many countries for the prevention and treatment of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    .) In a short-term study of 18 postmenopausal women with asymptomatic PHPT, raloxifene (60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for eight weeks) reduced mean serum calcium concentration by 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at a single time point (eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/82\">",
"     82",
"    </a>",
"    ]. Further data are needed before recommending raloxifene for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs on the horizon include calcitriol analogues that inhibit PTH secretion directly, but do not stimulate gastrointestinal calcium or phosphate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/83\">",
"     83",
"    </a>",
"    ], and drugs that block the PTH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF CONCOMITANT VITAMIN D DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency is common in patients with primary hyperparathyroidism (PHPT). Some individuals with vitamin D deficiency and hyperparathyroidism have more clinically significant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Classical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D repletion may improve some of the clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/86\">",
"     86",
"    </a>",
"    ]. However, there is concern that repleting vitamin D will worsen hypercalcemia and hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/87\">",
"     87",
"    </a>",
"    ]. In prospective studies of vitamin D repletion in patients with mild primary hyperparathyroidism, mean serum calcium concentrations did not increase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. As an example, one observational study reported no change in hypercalcemia in 21 individuals with mild PHPT (mean serum calcium 10.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and hypovitaminosis D (25OHD &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    treated with 50,000 International Units of vitamin D weekly for four weeks and then monthly thereafter to complete 12 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/88\">",
"     88",
"    </a>",
"    ]. However, urinary calcium excretion rose to exceed &gt;400",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hour in three patients, and in one patient serum calcium increased from 10.5 to 11.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6 to 3.0",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Due to the significant prevalence of vitamin D insufficiency in individuals with PHPT, the Third International Workshop on Asymptomatic Primary Hyperparathyroidism recommends measuring 25OHD in all patients with PHPT and repleting those with low levels (defined as &le;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    prior to making any management decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/47/8954/abstract/91\">",
"     91",
"    </a>",
"    ]. Specific repletion recommendations are not available from clinical trial data. Until such information becomes available, we suggest cautiously repleting vitamin D in patients with underlying hyperparathyroidism since worsening hypercalcemia and hypercalciuria have been reported in this setting.",
"   </p>",
"   <p>",
"    Regardless of the vitamin D dose, particular caution must be exercised in those individuals with vitamin D deficiency whose urinary calcium excretion is in the upper range of normal or frankly elevated. Once these individuals are vitamin D replete, their urinary calcium levels can rise quickly, increasing their risk for kidney stone formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Coexisting primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"       \"Patient information: Primary hyperparathyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/52/29507?source=see_link\">",
"       \"Patient information: Primary hyperparathyroidism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread identification of individuals with asymptomatic primary hyperparathyroidism raises the question of if and when these individuals should undergo surgery. Although parathyroidectomy improves bone density and may have modest effects on some quality of life symptoms, the majority of patients with asymptomatic PHPT do not have disease progression, as evidenced by stable biochemical abnormalities and BMD for up to a decade of observation. However, up to one-third of individuals with asymptomatic PHPT have evidence of disease progression (worsening hypercalcemia, hypercalciuria, newly diagnosed nephrolithiasis) over the first years of observation and would benefit from surgical intervention. In addition, BMD declines in most patients observed for longer than 8 to 10 years. Although these observational data are based upon a small number of patients, they do suggest that long-term (&gt;8 to 10 years) observation in asymptomatic patients is not optimal for skeletal outcomes.",
"   </p>",
"   <p>",
"    Guidelines for surgical intervention have been developed based upon risk for end-organ effects and for disease progression. Parathyroidectomy should be performed only by surgeons who are highly experienced and skilled in the operation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptomatic primary hyperparathyroidism should have parathyroid surgery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Candidates for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic individuals who meet the Third International Workshop on Asymptomatic Primary Hyperparathyroidism guidelines (",
"      <a class=\"graphic graphic_table graphicRef63054 \" href=\"UTD.htm?17/13/17628\">",
"       table 1",
"      </a>",
"      ),&nbsp;we suggest surgical intervention as opposed to observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Candidates for surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For asymptomatic individuals who do not meet surgical criteria, we monitor serum calcium and creatinine annually and bone density (hip, spine, and forearm) every one to two years. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Monitoring'",
"      </a>",
"      above.) If disease progression occurs (",
"      <a class=\"graphic graphic_table graphicRef63054 \" href=\"UTD.htm?17/13/17628\">",
"       table 1",
"      </a>",
"      ), we would proceed to surgery, as described above.",
"     </li>",
"     <li>",
"      For symptomatic patients who are medically unfit for surgery, we recommend medical therapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Alternatives to surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For such patients who are unable to have surgery and whose primary indication for surgery is symptomatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe hypercalcemia (particularly those in whom bone density is normal), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      rather than bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Calcimimetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic individuals who meet surgical criteria (low bone density, serum calcium elevated &ge;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      above the upper limit of normal) but who are medically unfit for surgery, we suggest medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Observation is an alternative option, particularly in patients whose primary indication for surgery is a reduced creatinine clearance. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For individuals who are unable to have surgery and whose primary indication for surgery is low bone mass and risk for fracture, we suggest bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals with PHPT and concomitant vitamin D deficiency (25-hydroxyvitamin D &le;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [50",
"      <span class=\"nowrap\">",
"       nmol/L]),",
"      </span>",
"      we suggest vitamin D repletion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such individuals, monitoring of serum and urine calcium to identify worsening hypercalcemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypercalciuria is necessary. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of concomitant vitamin D deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/1\">",
"      Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/2\">",
"      Silverberg SJ, Bilezikian JP. \"Incipient\" primary hyperparathyroidism: a \"forme fruste\" of an old disease. J Clin Endocrinol Metab 2003; 88:5348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/3\">",
"      Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004; 117:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/4\">",
"      Silverberg SJ, Bilezikian JP. Asymptomatic primary hyperparathyroidism: a medical perspective. Surg Clin North Am 2004; 84:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/5\">",
"      Mack LA, Pasieka JL. Asymptomatic primary hyperparathyroidism: a surgical perspective. Surg Clin North Am 2004; 84:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/6\">",
"      Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981; 56:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/7\">",
"      Heath H 3rd, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980; 302:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/8\">",
"      Utiger RD. Treatment of primary hyperparathyroidism. N Engl J Med 1999; 341:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/9\">",
"      Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med 1994; 96:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/10\">",
"      Kleerekoper M, Bilezkian JP. A cure in search of a disease: parathyroidectomy for nontraditional features of primary hyperparathyroidism. Am J Med 1994; 96:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/11\">",
"      Prager G, Kalaschek A, Kaczirek K, et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery 2002; 132:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/12\">",
"      Chiang CY, Andrewes DG, Anderson D, et al. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol (Oxf) 2005; 62:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/13\">",
"      Chan AK, Duh QY, Katz MH, et al. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg 1995; 222:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/14\">",
"      Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery 1995; 117:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/15\">",
"      Burney RE, Jones KR, Christy B, Thompson NW. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 1999; 125:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/16\">",
"      Pasieka JL, Parsons LL, Demeure MJ, et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg 2002; 26:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/17\">",
"      Sywak MS, Knowlton ST, Pasieka JL, et al. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyperparathyroidism? Surgery 2002; 132:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/18\">",
"      Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009; 94:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/19\">",
"      Walker MD, Silverberg SJ. Parathyroidectomy in asymptomatic primary hyperparathyroidism: improves \"bones\" but not \"psychic moans\". J Clin Endocrinol Metab 2007; 92:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/20\">",
"      Talpos GB, Bone HG 3rd, Kleerekoper M, et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 2000; 128:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/21\">",
"      Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007; 92:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/22\">",
"      Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007; 92:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/23\">",
"      Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004; 89:5415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/24\">",
"      Mollerup CL, Vestergaard P, Fr&oslash;kjaer VG, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002; 325:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/25\">",
"      Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/26\">",
"      Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/27\">",
"      Vestergaard P, Mollerup CL, Fr&oslash;kjaer VG, et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003; 27:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/28\">",
"      Nilsson IL, Yin L, Lundgren E, et al. Clinical presentation of primary hyperparathyroidism in Europe--nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 Suppl 2:N68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/29\">",
"      Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003; 327:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/30\">",
"      Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998; 104:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/31\">",
"      Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997; 82:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/32\">",
"      Lind L, Jacobsson S, Palm&eacute;r M, et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991; 230:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/33\">",
"      Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/34\">",
"      Bollerslev J, Rosen T, Mollerup CL, et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/35\">",
"      Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/36\">",
"      Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 1997; 21:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/37\">",
"      Abdelhadi M, Nordenstr&ouml;m J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:3845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/38\">",
"      Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/39\">",
"      Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:4007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/40\">",
"      Nomura R, Sugimoto T, Tsukamoto T, et al. Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism; a six-year longitudinal study with or without parathyroidectomy in a Japanese population. Clin Endocrinol (Oxf) 2004; 60:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/41\">",
"      Lumachi F, Camozzi V, Ermani M, et al. Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism: a prospective study. Ann N Y Acad Sci 2007; 1117:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/42\">",
"      Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/43\">",
"      Parisien M, Cosman F, Mellish RW, et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 1995; 10:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/44\">",
"      Ayturk S, Gursoy A, Bascil Tutuncu N, et al. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2006; 91:4260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/45\">",
"      Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996; 125:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/46\">",
"      Guo CY, Thomas WE, al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:3487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/47\">",
"      Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93:3462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/48\">",
"      El-Hajj Fuleihan G. Hyperparathyroidism: time to reconsider current clinical decision paradigms? J Clin Endocrinol Metab 2008; 93:3302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/49\">",
"      Wilson RJ, Rao S, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/50\">",
"      Vestergaard P, Mollerup CL, Fr&oslash;kjaer VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/51\">",
"      Khosla S, Melton J 3rd. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/52\">",
"      Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/53\">",
"      Palmer M, Adami HO, Bergstr&ouml;m R, et al. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/54\">",
"      Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988; 67:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/55\">",
"      Silverberg SJ, Brown I, Bilezikian JP. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 2002; 113:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/56\">",
"      Pachydakis A, Koutroumanis P, Geyushi B, Hanna L. Primary hyperparathyroidism in pregnancy presenting as intractable hyperemesis complicating psychogenic anorexia: a case report. J Reprod Med 2008; 53:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/57\">",
"      Truong MT, Lalakea ML, Robbins P, Friduss M. Primary hyperparathyroidism in pregnancy: a case series and review. Laryngoscope 2008; 118:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/58\">",
"      Kort KC, Schiller HJ, Numann PJ. Hyperparathyroidism and pregnancy. Am J Surg 1999; 177:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/59\">",
"      Chamarthi B, Greene MF, Dluhy RG. Clinical problem-solving. A problem in gestation. N Engl J Med 2011; 365:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/60\">",
"      McMullen TP, Learoyd DL, Williams DC, et al. Hyperparathyroidism in pregnancy: options for localization and surgical therapy. World J Surg 2010; 34:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/61\">",
"      Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv 2002; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/62\">",
"      Schnatz PF, Thaxton S. Parathyroidectomy in the third trimester of pregnancy. Obstet Gynecol Surv 2005; 60:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/63\">",
"      Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87:5353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/64\">",
"      Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/65\">",
"      Insogna KL, Mitnick ME, Stewart AF, et al. Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism. N Engl J Med 1985; 313:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/66\">",
"      Locker FG, Silverberg SJ, Bilezikian JP. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 1997; 102:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/67\">",
"      Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/68\">",
"      Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/69\">",
"      Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 2002; 87:4482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/70\">",
"      Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/71\">",
"      Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:3319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/72\">",
"      Silverberg SJ, Bone HG 3rd, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/73\">",
"      Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:5644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/74\">",
"      Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/75\">",
"      Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/76\">",
"      Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94:4860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/77\">",
"      Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 2011; 96:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/78\">",
"      Marcus R, Madvig P, Crim M, et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984; 100:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/79\">",
"      McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Miner Res 1994; 9:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/80\">",
"      Orr-Walker BJ, Evans MC, Clearwater JM, et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 2000; 160:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/81\">",
"      Fuliehan GE, Moore F Jr, LeBoff MS, et al. Longitudinal changes in bone density in hyperparathyroidism. J Clin Densitom 1999; 2:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/82\">",
"      Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/83\">",
"      Finch JL, Brown AJ, Kubodera N, et al. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993; 43:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/84\">",
"      Rosen HN, Lim M, Garber J, et al. The effect of PTH antagonist BIM-44002 on serum calcium and PTH levels in hypercalcemic hyperparathyroid patients. Calcif Tissue Int 1997; 61:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/85\">",
"      Carter PH, Liu RQ, Foster WR, et al. Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe. Proc Natl Acad Sci U S A 2007; 104:6846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/86\">",
"      Kantorovich V, Gacad MA, Seeger LL, Adams JS. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/87\">",
"      Bilezikian JP. Primary hyperparathyroidism. When to observe and when to operate. Endocrinol Metab Clin North Am 2000; 29:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/88\">",
"      Grey A, Lucas J, Horne A, et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005; 90:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/89\">",
"      Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 2009; 161:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/90\">",
"      Grubbs EG, Rafeeq S, Jimenez C, et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008; 144:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/47/8954/abstract/91\">",
"      Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2065 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8954=[""].join("\n");
var outline_f8_47_8954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGERY VERSUS MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Neuropsychiatric",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bone disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fracture risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Biochemical abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23978864\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CANDIDATES FOR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ALTERNATIVES TO SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preventive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Calcimimetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14645494\">",
"      - Estrogen-progestin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14645600\">",
"      - Raloxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF CONCOMITANT VITAMIN D DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2065\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2065|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/13/17628\" title=\"table 1\">",
"      Guidelines for surgery in asymptomatic PHPT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=related_link\">",
"      Calcium physiology in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/52/29507?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_47_8955="History for childhood hip pain";
var content_f8_47_8955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The history in the evaluation of acute hip pain in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to bear weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms in other joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Past history of hip symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of sports participation or trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent URI or febrile illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent antibiotic use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tick exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of systemic disease: weight loss, pallor, fatigue, rash, bowel irregularity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     URI: upper respiratory infection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8955=[""].join("\n");
var outline_f8_47_8955=null;
var title_f8_47_8956="Criteria for normal labor";
var content_f8_47_8956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for abnormal patterns in active labor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Labor pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nullipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multipara",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        First stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duration (no anesthesia)",
"       </td>",
"       <td>",
"        16.6 hours",
"       </td>",
"       <td>",
"        12.5 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duration (anesthesia)",
"       </td>",
"       <td>",
"        19.0 hours",
"       </td>",
"       <td>",
"        14.9 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protracted dilation",
"       </td>",
"       <td>",
"        &lt;1.2 cm/h",
"       </td>",
"       <td>",
"        &lt;1.5 cm/h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrested dilation",
"       </td>",
"       <td>",
"        &gt;2 h",
"       </td>",
"       <td>",
"        &gt;2 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Second stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duration (no anesthesia)",
"       </td>",
"       <td>",
"        132 minutes",
"       </td>",
"       <td>",
"        61 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duration (anesthesia)",
"       </td>",
"       <td>",
"        185 minutes",
"       </td>",
"       <td>",
"        131 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrest of descent (epidural)",
"       </td>",
"       <td>",
"        &gt;3 h",
"       </td>",
"       <td>",
"        &gt;2 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrest of descent (no epidural)",
"       </td>",
"       <td>",
"        &gt;2 h",
"       </td>",
"       <td>",
"        &gt;1 h",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Values represent approximately two standard deviations from the mean.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data compiled from: Kilpatrick SJ, Laros, RK. Obstet gynecol 1989; 74:85 and Friedman, EA, ed. Labor clinical evaluation and management. 2nd ed New York. Appleton-Century &mdash; Crofts, 1978 and American College of Obstetrics and Gynecology Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin Number 49, December 2003: Dystocia and augmentation of labor. Obstet Gynecol 2003; 102:1445.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8956=[""].join("\n");
var outline_f8_47_8956=null;
var title_f8_47_8957="Side effect pharm stress agents";
var content_f8_47_8957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of side effects (percent) with pharmacologic stress agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dipyridamole",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adenosine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dobutamine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regadenoson",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dizziness",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flushing",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpitations",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        49*",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresthesias",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST segment changes",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Major event",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        0.3",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        0.2",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        0.4",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fatal MI",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.05",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonfatal MI",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.05",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.2",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bronchospasm",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.15",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.16",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any side effect",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"     <br/>",
"     * Any cardiac arrhythmia as a consequence of dobutamine infusion.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Data not available.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Mahmarian JJ, Verani MS. Cardiol Clin 1994; 12:223.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8957=[""].join("\n");
var outline_f8_47_8957=null;
var title_f8_47_8958="Oxygen exchange in IPVDs";
var content_f8_47_8958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Proposed mechanism for partial response to oxygen in the hepatopulmonary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 192px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffusion-perfusion impairment (also called alveolar-capillary oxygen disequlibrium) occurs in the setting of vasodilation of alveolar capillaries; the partial pressure (or driving pressure) of oxygen in the alveolus is insufficient to achieve equilibration with blood moving near the center of the vessel. When alveolar oxygen is increased, the gradient for diffusion increases and oxygenation improves.",
"    <div class=\"footnotes\">",
"     P",
"     <sub>",
"      A",
"     </sub>",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     : partial pressure of alveolar oxygen; P",
"     <sub>",
"      a",
"     </sub>",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     : partial pressure of arterial oxygen; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8958=[""].join("\n");
var outline_f8_47_8958=null;
var title_f8_47_8959="Tongue protrusion";
var content_f8_47_8959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tongue protrusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Protrusion of the tongue beyond the mandibular alveolus facilitates latching on during lactation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tess E Isaacson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_47_8959=[""].join("\n");
var outline_f8_47_8959=null;
